Amedeo Smart

Free Medical Literature Service

 

Amedeo

Liver Diseases
  Free Subscription

Articles published in
Hepatology
    December 2025
  1. WANG X, Zhou Y, Zhang S, Farrar C, et al
    Targeting mTORC2-Dependent AKT/FOXO1/RNF125 signaling exploits a therapeutic vulnerability in c-MET-activated and beta-catenin-mutated hepatocellular carcinoma.
    Hepatology. 2025 Dec 2. doi: 10.1097/HEP.0000000000001637.
    >> Share

  2. PINTO E VAIRO F, Zimmermann MT, Wagenknecht J, Jorge SD, et al
    Discovery of a MET -driven monogenic cause of steatotic liver disease.
    Hepatology. 2025;82:1512-1522.
    >> Share

    November 2025
  3. ZAPATA-PAVAS LE, Serrano-Macia M, Merlos Rodrigo MA, Barrenechea-Barrenechea JA, et al
    NEDD8-specific protease 1 deficiency as a novel driver of hepatoblastoma development through dysregulation of the CAND1-NEDD8 pathway.
    Hepatology. 2025 Nov 14. doi: 10.1097/HEP.0000000000001614.
    >> Share

  4. HUANG X, Zhu T, Li S, Liu T, et al
    Development and validation of a non-invasive score for at-risk metabolic dysfunction-associated steatohepatitis in individuals with obesity undergoing bariatric surgery.
    Hepatology. 2025 Nov 13. doi: 10.1097/HEP.0000000000001612.
    >> Share

  5. MULIAWAN GK, Lee TKW
    Metabolic reprogramming in macrophages: A glutamine rescue in beta-catenin mutant hepatocellular carcinoma.
    Hepatology. 2025 Nov 13. doi: 10.1097/HEP.0000000000001619.
    >> Share

  6. ZHAO J, Hou L, Dery KJ, Yuan X, et al
    Hepatic ischemia reperfusion injury: Underlying mechanisms and concepts in liver surgery and liver transplantation.
    Hepatology. 2025 Nov 11. doi: 10.1097/HEP.0000000000001609.
    >> Share

  7. EL-KHOUEIRY AB, Kim RD, Harris WP, Sung MW, et al
    A multicenter dose-defining/expansion phase 1b study of first-line regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma.
    Hepatology. 2025 Nov 10. doi: 10.1097/HEP.0000000000001585.
    >> Share

  8. JIANG Y, Li Y, Wu T, Cao L, et al
    GPC3-based circular RNA vaccine suppresses hepatocellular carcinoma progression by activating adaptive immune responses.
    Hepatology. 2025 Nov 7. doi: 10.1097/HEP.0000000000001605.
    >> Share

  9. BANSAL MB, Patton H, Morgan TR, Carr RM, et al
    Semaglutide therapy for metabolic dysfunction-associated steatohepatitis: November 2025 updates to AASLD Practice Guidance.
    Hepatology. 2025 Nov 7. doi: 10.1097/HEP.0000000000001608.
    >> Share

  10. HUA H, Wang D, He L, Chen N, et al
    KLF9 drives intermittent hypoxia-induced NAFLD by suppressing the NR4A1-p38 MAPK hepatic metabolic axis.
    Hepatology. 2025 Nov 4. doi: 10.1097/HEP.0000000000001606.
    >> Share

  11. LEI Z, Wu Y, Xue W, Zhu D, et al
    Epigenetic repression of hepatocyte FoxO1 disrupts local immune homeostasis and promotes liver inflammation.
    Hepatology. 2025 Nov 4. doi: 10.1097/HEP.0000000000001590.
    >> Share

  12. HARTMANN P, Mouzaki M, Hassan S, Kehar M, et al
    Call to action-Pediatric MASLD requires immediate attention to curb health crisis.
    Hepatology. 2025;82:1341-1351.
    >> Share

  13. WANG L, Dong W, Fan L, Kong H, et al
    Repression of the ERRgamma-CYP2E1 pathway by FGF4 mitigates alcohol-associated liver injury.
    Hepatology. 2025;82:1138-1154.
    >> Share

  14. SERPER M, Tang H, Zhang S, McCullough A, et al
    Clinical outcomes and care for spontaneous bacterial peritonitis: A national cohort study.
    Hepatology. 2025;82:1187-1197.
    >> Share

  15. ROUSSEAU D, Bonnafous S, Soysouvanh F, Sarrail D, et al
    CD44 in myeloid cells is a major driver of liver inflammation and injury in alcohol-associated liver disease.
    Hepatology. 2025;82:1211-1228.
    >> Share

  16. NEWTON KP, Jayasekera D, Blackford AL, Behling C, et al
    Longitudinal response to standard of care in pediatric metabolic dysfunction-associated steatotic liver disease: Rates of improvement and worsening, and factors associated with outcomes.
    Hepatology. 2025;82:1198-1210.
    >> Share

  17. UNALP-ARIDA A, Ruhl CE
    Prevalence of metabolic dysfunction-associated steatotic liver disease and fibrosis defined by liver elastography in the United States using National Health and Nutrition Examination Survey 2017-March 2020 and August 2021-August 2023 data.
    Hepatology. 2025;82:1256-1273.
    >> Share

  18. NOUREDDIN M
    MASH clinical trials and drugs pipeline: An impending tsunami.
    Hepatology. 2025;82:1325-1340.
    >> Share

  19. WANG X, Zhang L, Dong B
    Molecular mechanisms in MASLD/MASH-related HCC.
    Hepatology. 2025;82:1303-1324.
    >> Share

  20. KHALID MB, Ilyas SI
    Surgical resection for hepatocellular carcinoma: Leave no TACE?
    Hepatology. 2025;82:1039-1040.
    >> Share

    October 2025
  21. WEI T, Ma ZJ, Guo S, Weiss M, et al
    Satellite lesions versus intrahepatic metastasis in multifocal intrahepatic cholangiocarcinoma: Prognostic impact and genomic profiling.
    Hepatology. 2025 Oct 30. doi: 10.1097/HEP.0000000000001594.
    >> Share

  22. HAN J, Zhao Y, Zhao J
    Yttrium-90 superiority in hepatocellular carcinoma downstaging: Treatment effect or selection bias?
    Hepatology. 2025 Oct 28. doi: 10.1097/HEP.0000000000001579.
    >> Share

  23. WALIA N, Hui S, Braude M
    Letter to the Editor: Assessing HCC incidence and surveillance thresholds in non-cirrhotic MASLD.
    Hepatology. 2025 Oct 23. doi: 10.1097/HEP.0000000000001586.
    >> Share

  24. GRIMAUD E, Gardin A, Ackermann O, Habes D, et al
    Serum bile acid levels predict the development of portal hypertension and high-risk esophageal varices following successful Kasai in biliary atresia.
    Hepatology. 2025 Oct 23. doi: 10.1097/HEP.0000000000001592.
    >> Share

  25. DELGADO ER, Patel P, Tao J, Krutsenko Y, et al
    Glutamine synthetase loss in beta-catenin-mutant hepatocellular carcinoma promotes tumor burden through macrophage metabolic reprogramming.
    Hepatology. 2025 Oct 23. doi: 10.1097/HEP.0000000000001591.
    >> Share

  26. JOHN BV, Bastaich D, Singal AG, Dahman B, et al
    Reply: Assessing HCC incidence and surveillance thresholds in non-cirrhotic MASLD.
    Hepatology. 2025 Oct 20. doi: 10.1097/HEP.0000000000001587.
    >> Share

  27. PATIDAR KR, Sharma P
    Time to focus on POCUS For AKI management in cirrhosis.
    Hepatology. 2025 Oct 16. doi: 10.1097/HEP.0000000000001583.
    >> Share

  28. ZHANG X, Gong H, Gu K, Chen D, et al
    Letter to the Editor: Re-evaluating the clinical relevance of the RIPPLY1-TBX19 Axis in CTNNB1-Mutant hepatocellular carcinoma.
    Hepatology. 2025 Oct 14. doi: 10.1097/HEP.0000000000001572.
    >> Share

  29. SALLMON H, Laufer G, Kurath-Koller S, Kramer P, et al
    Letter to the editor: Esophageal varices in Fontan patients - circulatory or hepatic failure?
    Hepatology. 2025 Oct 13. doi: 10.1097/HEP.0000000000001573.
    >> Share

  30. ABAD-JORDA L, Andres-Rozas M, Martinez-Alcocer A, Aspas J, et al
    Hepatocyte-derived extracellular vesicles promote endothelial dedifferentiation in chronic liver disease through the miR-153-3p - pyroptosis axis.
    Hepatology. 2025 Oct 10. doi: 10.1097/HEP.0000000000001567.
    >> Share

  31. MA H, Zhang VX, Tsui YM, Lee JM, et al
    Targeting sterol O-acyltransferase 1 rewires fatty acid metabolism and uncovers immune vulnerability in hepatocellular carcinoma.
    Hepatology. 2025 Oct 9. doi: 10.1097/HEP.0000000000001561.
    >> Share

  32. HUANG X, Lisman T
    Cirrhotic portal vein thrombosis as a vascular rather than a thrombotic disorder.
    Hepatology. 2025 Oct 8. doi: 10.1097/HEP.0000000000001565.
    >> Share

  33. ANTON A, Shalaby S, Botero ML, Blasi A, et al
    Endothelial-to-mesenchymal transition: A targetable mechanism that contributes to portal vein thrombosis in cirrhosis.
    Hepatology. 2025 Oct 6. doi: 10.1097/HEP.0000000000001547.
    >> Share

  34. FOERSTER F, Wiesmann L, Bark P, Galle PR, et al
    Pioneering precision: The evolution of immunotherapy for hepatocellular carcinoma.
    Hepatology. 2025 Oct 2. doi: 10.1097/HEP.0000000000001554.
    >> Share

    September 2025
  35. WANG X, Luo J, Han L, Xu T, et al
    FXR splicing by SF3B3 promotes MYC-driven hepatocarcinogenesis.
    Hepatology. 2025 Sep 23. doi: 10.1097/HEP.0000000000001523.
    >> Share

  36. PREMKUMAR M, Kajal K, Roy A, Izzy M, et al
    'Point-of-Care Ultrasound (POCUS) guided volume management and the effect of cirrhotic cardiomyopathy on acute kidney injury outcomes in cirrhosis'.
    Hepatology. 2025 Sep 23. doi: 10.1097/HEP.0000000000001524.
    >> Share

  37. DELTENRE P, Marot A, Henrion J
    A prognostic model in patients with alcohol-related cirrhosis does exist.
    Hepatology. 2025 Sep 17. doi: 10.1097/HEP.0000000000001532.
    >> Share

  38. PAN Z
    Letter to the editor: Technical considerations in the development of a multimodal deep learning model for predicting hepatocellular carcinoma outcomes.
    Hepatology. 2025 Sep 17. doi: 10.1097/HEP.0000000000001534.
    >> Share

  39. LIU TH, Yang HC
    Letter to the Editor: Clarifying the impact of response criteria and locoregional therapy on complete response outcomes in patients with hepatocellular carcinoma following immunotherapy.
    Hepatology. 2025 Sep 4. doi: 10.1097/HEP.0000000000001459.
    >> Share

  40. ZHANG L, Li H, Zong W, Li B, et al
    Letter to the Editor: Revisiting FOXP3 Expression and its prognostic implications in hepatocellular carcinoma.
    Hepatology. 2025 Sep 3. doi: 10.1097/HEP.0000000000001512.
    >> Share

  41. HUANG CH, Ku WT, Wu TH, Lin PT, et al
    Reply to the Letter to the Editor: Revisiting FOXP3 expression and its prognostic implications in hepatocellular carcinoma.
    Hepatology. 2025 Sep 3. doi: 10.1097/HEP.0000000000001515.
    >> Share

  42. LAI JC, Tapper E, Tandon P
    Integrative hepatology: Enhancing overall health to manage liver disease.
    Hepatology. 2025 Sep 3. doi: 10.1097/HEP.0000000000001516.
    >> Share

  43. JEONG JM, Choi SE, Shim YR, Kim HH, et al
    CX3CR1+ macrophages interact with HSCs to promote HCC through CD8+ T-cell suppression.
    Hepatology. 2025;82:655-668.
    >> Share

  44. LI W, Chi Y, Xiao X, Li J, et al
    Plasma FSTL-1 as a noninvasive diagnostic biomarker for patients with advanced liver fibrosis.
    Hepatology. 2025;82:669-682.
    >> Share

  45. YANG Y, Ni Q, Li H, Sun J, et al
    Genomic and the tumor microenvironment heterogeneity in multifocal hepatocellular carcinoma.
    Hepatology. 2025;82:582-598.
    >> Share

  46. ZHOU KQ, Zhong YC, Song MF, Sun YF, et al
    Distinct immune microenvironment of venous tumor thrombus in hepatocellular carcinoma at single-cell resolution.
    Hepatology. 2025;82:566-581.
    >> Share

  47. SINGAL AG, Quirk L, Boike J, Chernyak V, et al
    Value of HCC surveillance in a landscape of emerging surveillance options: Perspectives of a multi-stakeholder modified Delphi panel.
    Hepatology. 2025;82:794-809.
    >> Share

  48. PANG Z, Zhang H, Zheng S, Yang X, et al
    HNF4alpha-CDKL3 axis restricts MASLD progression by targeting FoxO1 via noncanonical phosphorylation.
    Hepatology. 2025;82:702-721.
    >> Share

  49. FACCIOLI LAP, Sun Y, Animasahun O, Motomura T, et al
    Human-induced pluripotent stem cell-based hepatic modeling of lipid metabolism-associated TM6SF2-E167K variant.
    Hepatology. 2025;82:638-654.
    >> Share

  50. ERICKSON H
    Hepatic stellate cells and macrophages: Key players in HCC immune suppression.
    Hepatology. 2025;82:545-546.
    >> Share

  51. WILECHANSKY RM
    Surging sludge: Intrahepatic cholangiocarcinoma mortality on the rise worldwide.
    Hepatology. 2025;82:543-544.
    >> Share

  52. ZHANGYUAN G, Yu W, Tian W, Xie J, et al
    RIPPLY1 suppresses cancer cell stemness via targeting TBX19 in CTNNB1-mutated hepatocellular carcinoma.
    Hepatology. 2025 Sep 1. doi: 10.1097/HEP.0000000000001483.
    >> Share

  53. SUN Y, Chen S, Xu X, Piao H, et al
    Early on-treatment LSM reliably predicts liver-related events in CHB patients with significant fibrosis and cirrhosis.
    Hepatology. 2025 Sep 1. doi: 10.1097/HEP.0000000000001504.
    >> Share

    August 2025
  54. HILSCHER MB
    The pressure is on: Elucidating hemodynamic profiles associated with esophageal varices in the Fontan circulation.
    Hepatology. 2025 Aug 26. doi: 10.1097/HEP.0000000000001510.
    >> Share

  55. ANANIA FA, Hager R, Higgins K, Makar GA, et al
    Non-Invasive Tests: Establishing efficacy for metabolic dysfunction associated steatohepatitis beyond the biopsy-current perspectives from the division of hepatology and nutrition, US Food and Drug Administration.
    Hepatology. 2025 Aug 26. doi: 10.1097/HEP.0000000000001509.
    >> Share

  56. DING J, She HY, Cheng Y, Sun HY, et al
    A novel mechanism involving USP53-regulated BSEP trafficking underlies low-GGT intrahepatic cholestasis.
    Hepatology. 2025 Aug 19. doi: 10.1097/HEP.0000000000001501.
    >> Share

  57. ZHOU SL, Yin D, Hu ZQ, Luo CB, et al
    Erratum: A positive feedback loop between cancer stem-like cells and tumor-associated neutrophils controls hepatocellular carcinoma progression.
    Hepatology. 2025 Aug 14. doi: 10.1097/HEP.0000000000001476.
    >> Share

  58. JOHN BV, Bastaich DR, Deng Y, Singal AG, et al
    Use of liver stiffness measurement for hepatocellular carcinoma risk stratification in metabolic dysfunction associated steatotic liver disease.
    Hepatology. 2025 Aug 14. doi: 10.1097/HEP.0000000000001498.
    >> Share

  59. INDRE MG, Leucuta DC, Lupsor-Platon M, Turco L, et al
    Diagnostic accuracy of 2D-SWE ultrasound for liver fibrosis assessment in MASLD: A multilevel random effects model meta-analysis.
    Hepatology. 2025;82:454-469.
    >> Share

  60. LOH JJ, Ng KY, Huang IB, Deng M, et al
    DGKH-mediated phosphatidic acid oncometabolism as a driver of self-renewal and therapy resistance in HCC.
    Hepatology. 2025;82:308-325.
    >> Share

  61. DRIESSEN S, Francque SM, Anker SD, Castro Cabezas M, et al
    Metabolic dysfunction-associated steatotic liver disease and the heart.
    Hepatology. 2025;82:487-503.
    >> Share

  62. SU T, Huang M, Liao J, Lin S, et al
    Erratum: Insufficient radiofrequency ablation promotes hepatocellular carcinoma metastasis through N6-methyladenosine mRNA methylation-dependent mechanism.
    Hepatology. 2025;82:E35-E36.
    >> Share

    July 2025
  63. ACUNA-PILARTE K, Reichert EC, Green YS, Halberg LM, et al
    Erratum: HAF prevents hepatocyte apoptosis and progression to MASH and HCC through transcriptional regulation of the NF-kappaB pathway.
    Hepatology. 2025 Jul 30. doi: 10.1097/HEP.0000000000001416.
    >> Share

  64. FAN G, Han X, Shi Y
    Reply: Reevaluating PCA and SCTransform usage in single-cell intrahepatic cholangiocarcinoma analysis.
    Hepatology. 2025 Jul 30. doi: 10.1097/HEP.0000000000001480.
    >> Share

  65. TAKEFUJI Y
    Letter to the editor: Reevaluating PCA and SCTransform usage in single-cell intrahepatic cholangiocarcinoma analysis.
    Hepatology. 2025 Jul 29. doi: 10.1097/HEP.0000000000001479.
    >> Share

  66. APODAKA-BIGURI M, Simao AL, Gonzalez-Romero F, Mestre D, et al
    E2F2 transcription factor promotes a cholestatic MASH phenotype by regulating hepatobiliary metabolism through miR-34a-5p.
    Hepatology. 2025 Jul 28. doi: 10.1097/HEP.0000000000001461.
    >> Share

  67. NAKIB D, MacParland S
    Decoding the PSC fibrotic niche: Hepatocyte stress and metallothioneins.
    Hepatology. 2025 Jul 25. doi: 10.1097/HEP.0000000000001478.
    >> Share

  68. HUANG Q, Wang W, Ge Q, Xu D, et al
    NEK7 induced phosphorylation of EGFR on serine 1070 drive the acquired lenvatinib resistance in hepatocellular carcinoma.
    Hepatology. 2025 Jul 22. doi: 10.1097/HEP.0000000000001474.
    >> Share

  69. SEIF EL DAHAN K, Daher D, Rich NE, Nayak AJ, et al
    Causes of mortality among patients with early-stage hepatocellular carcinoma.
    Hepatology. 2025 Jul 22. doi: 10.1097/HEP.0000000000001471.
    >> Share

  70. TELLEZ L, Toledano M, Alvarez M, Garrido-Lestache E, et al
    Distinctive hemodynamic phenotype in Fontan-type circulation patients with distal esophageal varices.
    Hepatology. 2025 Jul 22. doi: 10.1097/HEP.0000000000001472.
    >> Share

  71. ABRUZZESE GA, Martinez-Chantar ML
    Minor players, major signals: Unveiling the systemic and gut-localized impact of microbial amidated bile acids in hepatopancreatobiliary disease.
    Hepatology. 2025 Jul 21. doi: 10.1097/HEP.0000000000001473.
    >> Share

  72. BAJAJ JS, Reddy KR, Tandon P, Lai JC, et al
    Salivary microbiome and serum metabolomics add to clinical biomarkers to predict 6-month hospitalizations in a multi-center cirrhosis outpatient cohort.
    Hepatology. 2025 Jul 9. doi: 10.1097/HEP.0000000000001462.
    >> Share

  73. SCHEINER B, Pinter M
    Reply: Clarifying the impact of response criteria and locoregional therapy on complete response outcomes in patients with hepatocellular carcinoma following immunotherapy.
    Hepatology. 2025 Jul 7. doi: 10.1097/HEP.0000000000001460.
    >> Share

  74. SU TH, Shin EC
    Peripheral blood Foxp3-High tregs: A novel prognostic biomarker in hepatocellular carcinoma.
    Hepatology. 2025 Jul 7. doi: 10.1097/HEP.0000000000001464.
    >> Share

  75. SINHA S, Ali Q, Zhang T, T-Nguyen DH, et al
    Aging disrupts hepatocyte zonation homeostasis in mice and humans.
    Hepatology. 2025 Jul 4. doi: 10.1097/HEP.0000000000001451.
    >> Share

  76. GUO Y, Zhang Q, Li B, Dai W, et al
    Biliary YB-1/GLI2 axis facilitates ductular reaction and promotes hepatic stellate cell activation via SPP1/Integrin alphavbeta1 signaling during liver fibrogenesis.
    Hepatology. 2025 Jul 4. doi: 10.1097/HEP.0000000000001458.
    >> Share

  77. CHONG LUGON N, Rabiee A, Mezzacappa C, Kaplan DE, et al
    Prognostic significance of mild ascites in patients with cirrhosis.
    Hepatology. 2025 Jul 3. doi: 10.1097/HEP.0000000000001452.
    >> Share

  78. TRAUNER M, Karpen SJ, Dawson PA
    Benefits and challenges to therapeutic targeting of bile acid circulation in cholestatic liver disease.
    Hepatology. 2025 Jul 2. doi: 10.1097/HEP.0000000000001438.
    >> Share

  79. UNTALAN M, A Crimmins N, Yates KP, A Mencin A, et al
    Prevalence of subclinical hypothyroidism and longitudinal thyroid-stimulating hormone changes in youth with metabolic dysfunction-associated steatotic liver disease: An observational study.
    Hepatology. 2025;82:155-164.
    >> Share

  80. SALIBA-GUSTAFSSON P, Justesen JM, Ranta A, Sharma D, et al
    A functional genomic framework to elucidate novel causal metabolic dysfunction-associated fatty liver disease genes.
    Hepatology. 2025;82:165-183.
    >> Share

  81. HAI S, Li X, Xie E, Wu W, et al
    Intestinal IL-33 promotes microbiota-derived trimethylamine N -oxide synthesis and drives metabolic dysfunction-associated steatotic liver disease progression by exerting dual regulation on HIF-1alpha.
    Hepatology. 2025;82:184-198.
    >> Share

  82. DIAZ LA, Winder GS, Leggio L, Bajaj JS, et al
    New insights into the molecular basis of alcohol abstinence and relapse in alcohol-associated liver disease.
    Hepatology. 2025;82:254-271.
    >> Share

  83. ADLAT S, Vazquez Salgado AM, Lee M, Yin D, et al
    Emerging and potential use of CRISPR in human liver disease.
    Hepatology. 2025;82:232-253.
    >> Share

  84. HUANG CH, Ku WT, Mahalingam J, Wu CH, et al
    Tumor-migrating peripheral Foxp3-high regulatory T cells drive poor prognosis in hepatocellular carcinoma.
    Hepatology. 2025 Jul 1. doi: 10.1097/HEP.0000000000001428.
    >> Share

  85. XU X, Li H, Lin H, Li Q, et al
    MIF-mediated crosstalk between THRSP+ hepatocytes and CD74+ lipid-associated macrophages in hepatic periportal zone drives MASH.
    Hepatology. 2025 Jul 1. doi: 10.1097/HEP.0000000000001429.
    >> Share

    June 2025
  86. NAM H, Kim DY, Kim DY, Kim JH, et al
    Development and validation of a risk prediction model for patients with hepatocellular carcinoma receiving atezolizumab-bevacizumab.
    Hepatology. 2025 Jun 30. doi: 10.1097/HEP.0000000000001444.
    >> Share

  87. ZHANG L, Han C, Shrestha MM, Le J, et al
    The OGT-TFF2 axis mediates intrahepatic crosstalk and MASH pathogenesis.
    Hepatology. 2025 Jun 30. doi: 10.1097/HEP.0000000000001445.
    >> Share

  88. XIAOFANG S, Zhanhui O, Ruochan C, Xiaohua N, et al
    Erratum: Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells.
    Hepatology. 2025 Jun 25. doi: 10.1097/HEP.0000000000001384.
    >> Share

  89. LI J, Xu L, Rui F, Tran S, et al
    Type 2 Diabetes mellitus as an independent predictor of significant fibrosis in treatment-naive chronic hepatitis B patients with concurrent hepatic steatosis.
    Hepatology. 2025 Jun 25. doi: 10.1097/HEP.0000000000001442.
    >> Share

  90. YANG DL, Ye L, Zeng FJ, Liu J, et al
    Erratum: Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in
    Hepatology. 2025 Jun 25. doi: 10.1097/HEP.0000000000001401.
    >> Share

  91. TEMPRANO AG, Romero MR, Ghallab A, Llera L, et al
    Gut-to-Bile transfer of microbially amidated minor bile acids in patients with hepatopancreatobiliary disorders.
    Hepatology. 2025 Jun 23. doi: 10.1097/HEP.0000000000001441.
    >> Share

  92. TAO J, Wang J
    Reply: Considerations on the specific role of LHX2 in the process of hepatic stellate cells regulating hepatocyte function.
    Hepatology. 2025 Jun 18. doi: 10.1097/HEP.0000000000001435.
    >> Share

  93. NI J, Zhai D, Li J, Li B, et al
    Letter to editor: Considerations on the specific role of LHX2 in the process of hepatic stellate cells regulating hepatocyte function.
    Hepatology. 2025 Jun 16. doi: 10.1097/HEP.0000000000001434.
    >> Share

  94. SU JY, Li JR, Pan LX, Ma YL, et al
    Tertiary lymphoid structures in hepatocellular carcinoma: Influence on immune cell profiles in tumors and on efficacy of adjuvant PD-1 inhibitor therapy after hepatectomy.
    Hepatology. 2025 Jun 11. doi: 10.1097/HEP.0000000000001433.
    >> Share

  95. SHAW J, Acharya C, Fagan A, Olofson A, et al
    Health IT interventions reduce avoidable readmissions in cirrhosis: The HEROIC randomized controlled trial.
    Hepatology. 2025 Jun 11. doi: 10.1097/HEP.0000000000001424.
    >> Share

  96. LI F, Li Y, Wang L, Xu L, et al
    Tumor microenvironment heterogeneity and progression mechanisms in intrahepatic cholangiocarcinoma: A study based on single-cell and spatial transcriptomic sequencing.
    Hepatology. 2025 Jun 9. doi: 10.1097/HEP.0000000000001423.
    >> Share

  97. PEDDU DK, Tedesco N, Rutledge SM, Wijarnpreecha K, et al
    Social determinants of health influence the risk of cirrhosis: A diverse nationwide cohort study.
    Hepatology. 2025 Jun 9. doi: 10.1097/HEP.0000000000001420.
    >> Share

  98. BIAN Q, Wang S, Song Z, Liu F, et al
    Arid1a deficiency promotes hepatocyte hyperpolyploidy and drives intrahepatic cholangiocarcinoma in mice.
    Hepatology. 2025 Jun 9. doi: 10.1097/HEP.0000000000001422.
    >> Share

  99. WANG H, Wang S, Lei Y, Chen Y, et al
    Serum amyloid A1-Induced intrahepatic regulatory T cell dysfunction drives autoimmune hepatitis progression.
    Hepatology. 2025 Jun 9. doi: 10.1097/HEP.0000000000001419.
    >> Share

  100. MANDORFER M, Jachs M, Semmler G
    Roadmap for a generally accepted model to predict first hepatic decompensation in compensated advanced chronic liver disease.
    Hepatology. 2025 Jun 9. doi: 10.1097/HEP.0000000000001431.
    >> Share

  101. LIANG BG, Zheng YM, Xu MH, Gao C, et al
    The MASTL/YBX1/PAK4 axis regulated by stress-activated STK24 triggers lenvatinib resistance and tumor progression in hepatocellular carcinoma.
    Hepatology. 2025 Jun 2. doi: 10.1097/HEP.0000000000001392.
    >> Share

  102. TINCOPA MA, Diaz LA, Huang DQ, Arab JP, et al
    Disparities in screening and risk stratification for Hispanic adults with metabolic dysfunction-associated steatotic liver disease.
    Hepatology. 2025;81:1792-1804.
    >> Share

  103. MARINO Z, Garcia-Sola C, Rios J, Bono A, et al
    Exchangeable copper for patients with Wilson disease at follow-up: Rethinking normal ranges or changing methodology.
    Hepatology. 2025;81:1728-1739.
    >> Share

  104. FAN L, Tian C, Yang W, Liu X, et al
    HKDC1 promotes liver cancer stemness under hypoxia through stabilizing beta-catenin.
    Hepatology. 2025;81:1685-1699.
    >> Share

  105. BAKRANIA A, Mo Y, Zheng G, Bhat M, et al
    RNA nanomedicine in liver diseases.
    Hepatology. 2025;81:1847-1877.
    >> Share

  106. MACHIDA K, Tsukamoto H, Liu JC, Han YP, et al
    Retraction: C-Jun mediates hepatitis C virus hepatocarcinogenesis through signal transducer and activator of transcription 3 and nitric oxide-dependent impairment of oxidative DNA repair.
    Hepatology. 2025;81:E181.
    >> Share

  107. JIANG JX, Fish SR, Tomilov A, Li Y, et al
    Erratum: Nonphagocytic activation of NOX2 is implicated in progressive nonalcoholic steatohepatitis during aging.
    Hepatology. 2025;81:E180.
    >> Share

  108. HARRIS K
    LPCN 1148: Rebuilding muscle memory in cirrhosis patients.
    Hepatology. 2025;81:1625-1626.
    >> Share

  109. EISWERTH M, Arab JP
    A new voice in diagnosing and predicting hepatic encephalopathy.
    Hepatology. 2025;81:1623-1624.
    >> Share

    May 2025
  110. NGUYEN T, Shin Y, Ruppa A, Krall AS, et al
    Galectin-1 modulates glycolysis via a GM1-galactose-dependent pathway to promote hyperthermia resistance in hepatocellular carcinoma.
    Hepatology. 2025 May 21. doi: 10.1097/HEP.0000000000001391.
    >> Share

  111. XIE L, Chen H, Zhang L, Yang YY, et al
    Suppressing MASH fibrotic progression by blocking succinate-GPR91 signaling in hepatic stellate cells.
    Hepatology. 2025 May 19. doi: 10.1097/HEP.0000000000001405.
    >> Share

  112. REGHUPATY SC, Raha S, Mendoza R, Manna D, et al
    TATA-box binding protein associated factor 2 (TAF2) in hepatocyte survival and tumorigenesis.
    Hepatology. 2025 May 19. doi: 10.1097/HEP.0000000000001406.
    >> Share

  113. LAU G, Sangro B, Cheng AL, Kudo M, et al
    Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable hepatocellular carcinoma: HIMALAYA phase 3 randomized clinical trial.
    Hepatology. 2025 May 16. doi: 10.1097/HEP.0000000000001385.
    >> Share

  114. JIN Y, Wang M, Xu A, Xu B, et al
    Letter to the Editor: Association between mean arterial pressure and terlipressin in the reversal of hepatorenal syndrome-acute kidney injury.
    Hepatology. 2025 May 15. doi: 10.1097/HEP.0000000000001404.
    >> Share

  115. WANG Y, Yang L, Li M, Hao J, et al
    Proenkephalin produced by neonatal T-bet+ Treg cells promotes periportal hepatocyte maturation.
    Hepatology. 2025 May 12. doi: 10.1097/HEP.0000000000001389.
    >> Share

  116. WANG C, Dong D, Zhao N, Zhao S, et al
    Hepatocyte-specific C-C motif chemokine ligand 9 signaling promotes liver fibrosis progression in mice.
    Hepatology. 2025 May 9. doi: 10.1097/HEP.0000000000001393.
    >> Share

  117. YANG DL, Li YF, Li YJ, Qiu GG, et al
    Reply: Survival benefit of transarterial chemoembolization combined with tyrosine kinase and immune checkpoint inhibitors as conversion therapy for unresectable hepatocellular carcinoma needs more details.
    Hepatology. 2025 May 9. doi: 10.1097/HEP.0000000000001395.
    >> Share

  118. YU TC, Zhao L, Sze KM, Tian L, et al
    GPD1L supports glycerol-3-phosphate and triacylglycerol synthesis and promotes tumor progression in hepatocellular carcinoma.
    Hepatology. 2025 May 9. doi: 10.1097/HEP.0000000000001394.
    >> Share

  119. GENG Y, Schwabe RF
    Hepatic stellate cell heterogeneity: Functional aspects and therapeutic implications.
    Hepatology. 2025 May 8. doi: 10.1097/HEP.0000000000001386.
    >> Share

  120. O'ROURKE CJ, Andersen JB
    Intrahepatic Cholangiocarcinoma PANoptosidy.
    Hepatology. 2025 May 8. doi: 10.1097/HEP.0000000000001398.
    >> Share

  121. WANG D, Yi S, Liu X
    Letter to the editor: Survival benefit of transarterial chemoembolization combined with tyrosine kinase and immune checkpoint inhibitors as conversion therapy for unresectable hepatocellular carcinoma needs more details.
    Hepatology. 2025 May 8. doi: 10.1097/HEP.0000000000001390.
    >> Share

  122. YANG Z, Jiang Y, Ma J, Wang L, et al
    LncRNA H19 promoted alcohol-associated liver disease through dysregulation of alternative splicing and methionine metabolism.
    Hepatology. 2025;81:1485-1500.
    >> Share

  123. SUN Y, Wei H, Yu W, Gao H, et al
    The actin-binding protein drebrin disrupts NF2-LATS kinases complex assembly to facilitate liver tumorigenesis.
    Hepatology. 2025;81:1433-1451.
    >> Share

  124. ZHANG S, Yan Y, Zeng XF, Gu Y, et al
    Associations of the EAT-Lancet reference diet with metabolic dysfunction-associated steatotic liver disease and its severity: A multicohort study.
    Hepatology. 2025;81:1583-1594.
    >> Share

  125. HUANG DQ, Wilson LA, Behling C, Amangurbanova M, et al
    Liver stiffness progression in biopsy-proven metabolic dysfunction-associated steatotic disease among people with diabetes versus people without diabetes: A prospective multicenter study.
    Hepatology. 2025;81:1553-1563.
    >> Share

  126. OLUBAMIWA AO, Liao TJ, Zhao J, Dehanne P, et al
    Drug interaction with UDP-Glucuronosyltransferase (UGT) enzymes is a predictor of drug-induced liver injury.
    Hepatology. 2025;81:1512-1521.
    >> Share

  127. MONIAUX N, Geoffre N, Deshayes A, Dos Santos A, et al
    Tumor suppressive role of the antimicrobial lectin REG3A targeting the O -GlcNAc glycosylation pathway.
    Hepatology. 2025;81:1416-1432.
    >> Share

  128. NOVOA E, da Silva Lima N, Gonzalez-Rellan MJ, Chantada-Vazquez MDP, et al
    Mitochondrial antiviral signaling protein enhances MASLD progression through the ERK/TNFalpha/NFkappabeta pathway.
    Hepatology. 2025;81:1535-1552.
    >> Share

  129. DE RUDDER M, Manco R, Coubeau L, Fontaine A, et al
    Vascular damage and excessive proliferation compromise liver function after extended hepatectomy in mice.
    Hepatology. 2025;81:1468-1484.
    >> Share

  130. NORDEN-KRICHMAR TM, Rotroff D, Schwantes-An TH, Bataller R, et al
    Genomic approaches to explore susceptibility and pathogenesis of alcohol use disorder and alcohol-associated liver disease.
    Hepatology. 2025;81:1595-1606.
    >> Share

  131. CHAGANTI J, Zeng G, Patil A, Lockart I, et al
    Altered blood-brain barrier permeability is associated with abnormal distant connectivity and regional homogeneity in covert hepatic encephalopathy - a cross sectional study.
    Hepatology. 2025 May 1. doi: 10.1097/HEP.0000000000001343.
    >> Share

  132. ZHANG Q, Song Q, Liu Y, Li J, et al
    Letter to the Editor: Redefining post-resection care: Critical analysis of adjuvant TACE in curative hepatocellular carcinoma management.
    Hepatology. 2025 May 1. doi: 10.1097/HEP.0000000000001327.
    >> Share

    April 2025
  133. YAO J, Liu P, Teng X, Kong D, et al
    Alcohol-induced disruption of hepatic m6A modification exacerbates alcohol-associated steatohepatitis by impairing liver immune microenvironment homeostasis.
    Hepatology. 2025 Apr 30. doi: 10.1097/HEP.0000000000001374.
    >> Share

  134. FUJIWARA N, Matsushita Y, Tempaku M, Tachi Y, et al
    AI-based phenotyping of hepatic fiber morphology to inform molecular alterations in metabolic dysfunction-associated steatotic liver disease.
    Hepatology. 2025 Apr 22. doi: 10.1097/HEP.0000000000001360.
    >> Share

  135. FIX OK, Kane M, Gainey CS, Khairat S, et al
    Privacy and fidelity: The promise of synthetic data in hepatology research.
    Hepatology. 2025 Apr 21. doi: 10.1097/HEP.0000000000001361.
    >> Share

  136. WANG J, Zhang S, Fan T, Wu C, et al
    Letter to the Editor: Association of hepatitis B surface antigen and risk of hepatocellular carcinoma in chronic hepatitis B patients with immune-tolerant phase.
    Hepatology. 2025 Apr 21. doi: 10.1097/HEP.0000000000001365.
    >> Share

  137. HUI VW, Wong GL, Dai J, Tse YK, et al
    Increased risk of hepatocellular carcinoma in HBeAg-negative indeterminate phase compared to HBeAg-negative chronic infection.
    Hepatology. 2025 Apr 21. doi: 10.1097/HEP.0000000000001354.
    >> Share

  138. TSENG TC, Kao JH
    Reply: Association of hepatitis B surface antigen and risk of hepatocellular carcinoma in chronic hepatitis B patients with immune-tolerant phase.
    Hepatology. 2025 Apr 21. doi: 10.1097/HEP.0000000000001366.
    >> Share

  139. HOLMER M, Ingre M, Farkkila M, Ponsioen C, et al
    Cirrhosis and age are key determinants of HCC risk in individuals with primary sclerosing cholangitis: A multicenter longitudinal cohort study.
    Hepatology. 2025 Apr 16. doi: 10.1097/HEP.0000000000001351.
    >> Share

  140. YU Y, You Y, Duan Y, Kang M, et al
    Multiomics approaches for identifying the PANoptosis signature and prognostic model via a multimachine-learning computational framework for intrahepatic cholangiocarcinoma.
    Hepatology. 2025 Apr 15. doi: 10.1097/HEP.0000000000001352.
    >> Share

  141. ROCCARINA D, Saltini D, Senzolo M, Nardelli S, et al
    Reply: Post-TIPS hemodynamic target adherence fails to improve outcomes in cirrhotic patients.
    Hepatology. 2025 Apr 8. doi: 10.1097/HEP.0000000000001350.
    >> Share

  142. TANTAI X, Li L, Dai S
    Letter to the editor: Considerations on the use of LPCN 1148 in cirrhotic patients with sarcopenia.
    Hepatology. 2025 Apr 8. doi: 10.1097/HEP.0000000000001347.
    >> Share

  143. TANTAI X, Li L, Dai S
    Letter to the editor: Post-TIPS hemodynamic target adherence fails to improve outcomes in cirrhotic patients.
    Hepatology. 2025 Apr 8. doi: 10.1097/HEP.0000000000001349.
    >> Share

  144. BRUNO BJ, Weavil JC, Ogle J, Chidambaram N, et al
    Reply: Considerations on the use of LPCN 1148 in cirrhotic patients with sarcopenia.
    Hepatology. 2025 Apr 8. doi: 10.1097/HEP.0000000000001348.
    >> Share

  145. YANG LX, Gao Q, Shi JY, Wang ZC, et al
    Erratum: Mitogen-activated protein kinase kinase kinase 4 deficiency in intrahepatic cholangiocarcinoma leads to invasive growth and epithelial-mesenchymal transition.
    Hepatology. 2025 Apr 7. doi: 10.1097/HEP.0000000000001274.
    >> Share

  146. LAI JC, Lok AS
    Accurate prediction of hepatocellular carcinoma risk in patients with chronic HBV infection: HBeAg status and HBsAg level matter.
    Hepatology. 2025 Apr 3. doi: 10.1097/HEP.0000000000001345.
    >> Share

  147. WANG B, Hsu SH, Wang X, Kutay H, et al
    Erratum: Reciprocal regulation of microRNA-122 and c-Myc in hepatocellular cancer: Role of E2F1 and transcription factor dimerization partner 2.
    Hepatology. 2025 Apr 3. doi: 10.1097/HEP.0000000000001261.
    >> Share

  148. NOBEL YR, Boike JR, Mazumder NR, Thornburg B, et al
    Predictors of long-term clinical outcomes after TIPS: An ALTA group study.
    Hepatology. 2025;81:1244-1255.
    >> Share

  149. OJHA U, Kim S, Rhee CY, You J, et al
    Endothelial RUNX3 controls LSEC dysfunction and angiocrine LRG1 signaling to prevent liver fibrosis.
    Hepatology. 2025;81:1228-1243.
    >> Share

  150. LEFERE S, Mosca A, Hudert C, Dupont E, et al
    Development and validation of pFIB scores for exclusion of significant liver fibrosis in pediatric MASLD.
    Hepatology. 2025;81:1276-1287.
    >> Share

  151. HLADY RA, Zhao X, El Khoury LY, Wagner RT, et al
    Epigenetic heterogeneity hotspots in human liver disease progression.
    Hepatology. 2025;81:1197-1210.
    >> Share

  152. STALLER DW, Panigrahi SS, Jayasinghe YP, Dong Y, et al
    A novel phosphodiesterase inhibitor for the treatment of chronic liver injury and metabolic diseases.
    Hepatology. 2025;81:1288-1303.
    >> Share

  153. ZANUSO V, Rimassa L, Braconi C
    The rapidly evolving landscape of HCC: Selecting the optimal systemic therapy.
    Hepatology. 2025;81:1365-1386.
    >> Share

  154. KUREBAYASHI Y, Sakamoto M
    Macrotrabecular hepatocellular carcinoma: Unique immunovascular characteristics.
    Hepatology. 2025 Apr 1. doi: 10.1097/HEP.0000000000001339.
    >> Share

  155. MOL B, Werner E, Culver EL, van der Meer AJ, et al
    Epidemiological and economical burden of cholestatic liver disease.
    Hepatology. 2025 Apr 1. doi: 10.1097/HEP.0000000000001341.
    >> Share

    March 2025
  156. AHN JC, Ng WH, Yeo YH, Kim HS, et al
    Comparative effectiveness of immunotherapy versus lenvatinib in advanced hepatocellular carcinoma: A real-world analysis using target trial emulation.
    Hepatology. 2025 Mar 28. doi: 10.1097/HEP.0000000000001328.
    >> Share

  157. GUO Y, Wang J, Zhang L, Shen S, et al
    Erratum: Theranostical nanosystem-mediated identification of an oncogene and highly effective therapy in hepatocellular carcinoma.
    Hepatology. 2025 Mar 27. doi: 10.1097/HEP.0000000000001240.
    >> Share

  158. KIM KE, Lee J, Shin HJ, Jeong EA, et al
    Erratum: Lipocalin-2 activates hepatic stellate cells and promotes nonalcoholic steatohepatitis in high-fat diet-fed Ob/Ob mice.
    Hepatology. 2025 Mar 27. doi: 10.1097/HEP.0000000000001287.
    >> Share

  159. MACIAS RIR, Roessler S, Verstegen MMA
    Deciphering the spatial tumor microenvironment in intrahepatic cholangiocarcinoma.
    Hepatology. 2025 Mar 24. doi: 10.1097/HEP.0000000000001322.
    >> Share

  160. SU R, Tao X, Yan L, Liu Y, et al
    Early screening, diagnosis and recurrence monitoring of hepatocellular carcinoma in chronic hepatitis B patients based on serum N-glycomics analysis: A cohort study.
    Hepatology. 2025 Mar 21. doi: 10.1097/HEP.0000000000001316.
    >> Share

  161. TSENG TC, Hosaka T, Pan MH, Liu CJ, et al
    Higher level of Hepatitis B Surface antigen associated with delayed development of hepatocellular carcinoma in immune-tolerant patients.
    Hepatology. 2025 Mar 20. doi: 10.1097/HEP.0000000000001313.
    >> Share

  162. WONG CC, Wong CM
    CAD-Driven pathways in hepatocellular carcinoma metastasis.
    Hepatology. 2025 Mar 19. doi: 10.1097/HEP.0000000000001315.
    >> Share

  163. CHEN S, Shen L, Fan W
    Letter to the Editor: The divergences in the efficacy of adjuvant transarterial chemoembolization for hepatocellular carcinoma: In-depth analysis and enlightenments.
    Hepatology. 2025 Mar 18. doi: 10.1097/HEP.0000000000001310.
    >> Share

  164. ZHANG T, Huang CJ, Chen HT, Huang YH, et al
    HLA-DQB1*03:01 and risk of Hepatitis B virus-related hepatocellular carcinoma.
    Hepatology. 2025 Mar 14. doi: 10.1097/HEP.0000000000001307.
    >> Share

  165. ZHAO Q, Liu H, Yang Z, Han X, et al
    Pre-B-Cell leukemia transcription factor 1 contributes to liver fibrosis by enabling IL-7 signaling in hepatic stellate cells.
    Hepatology. 2025 Mar 13. doi: 10.1097/HEP.0000000000001302.
    >> Share

  166. PAN J, Zhang M, Rao D, Ma J, et al
    CAD manipulates tumor intrinsic DHO/UBE4B/NF-kappaB pathway and fuels macrophage cross-talk, promoting hepatocellular carcinoma metastasis.
    Hepatology. 2025 Mar 12. doi: 10.1097/HEP.0000000000001304.
    >> Share

  167. MONTAGNESE S, Duarte-Rojo A
    Hepatic encephalopathy - We are no longer those who believe that reality is what we perceive.
    Hepatology. 2025 Mar 12. doi: 10.1097/HEP.0000000000001308.
    >> Share

  168. LI PJ, Tabrizian P, Daher D, Gaviria F, et al
    A prospective multicenter validation of RETREAT for post-transplantation hepatocellular carcinoma recurrence prediction.
    Hepatology. 2025 Mar 11. doi: 10.1097/HEP.0000000000001297.
    >> Share

  169. AHN JC, Noh YK, Hu M, Shen X, et al
    AI-driven synthetic data generation for accelerating hepatology research: A study of the United Network for Organ Sharing (UNOS) database.
    Hepatology. 2025 Mar 11. doi: 10.1097/HEP.0000000000001299.
    >> Share

  170. WANG P, Zhong L
    Letter to the Editor: Downstaging of hepatocellular carcinoma before liver transplantation: More details, more significance.
    Hepatology. 2025 Mar 10. doi: 10.1097/HEP.0000000000001301.
    >> Share

  171. XU E, Mehta N
    Reply: Downstaging of hepatocellular carcinoma before liver transplantation.
    Hepatology. 2025 Mar 10. doi: 10.1097/HEP.0000000000001303.
    >> Share

  172. CULLARO G, Allegretti AS, Patidar KR, Jamil K, et al
    The relationship between mean arterial pressure and terlipressin in hepatorenal syndrome-acute kidney injury reversal: a post hoc analysis.
    Hepatology. 2025 Mar 7. doi: 10.1097/HEP.0000000000001295.
    >> Share

  173. MOECKLI B, Wassmer CH, El Hajji S, Kumar R, et al
    Determining safe washout period for immune checkpoint inhibitors prior to liver transplantation: An international retrospective cohort study.
    Hepatology. 2025 Mar 5. doi: 10.1097/HEP.0000000000001289.
    >> Share

  174. SUN Y, Li T, Ding L, Wang J, et al
    Platelet-mediated circulating tumor cell evasion from natural killer cell killing through immune checkpoint CD155-TIGIT.
    Hepatology. 2025;81:791-807.
    >> Share

  175. NAKATSUKA T, Tateishi R, Sato M, Hashizume N, et al
    Deep learning and digital pathology powers prediction of HCC development in steatotic liver disease.
    Hepatology. 2025;81:976-989.
    >> Share

  176. SASAKI K, Rooge S, Gunewardena S, Hintz JA, et al
    Kupffer cell diversity maintains liver function in alcohol-associated liver disease.
    Hepatology. 2025;81:870-887.
    >> Share

  177. HAN S, Fan H, Zhong G, Ni L, et al
    Nuclear KRT19 is a transcriptional corepressor promoting histone deacetylation and liver tumorigenesis.
    Hepatology. 2025;81:808-822.
    >> Share

  178. KIM D, Shah M, Kim JH, Kim J, et al
    Integrative transcriptomic and genomic analyses unveil the IFI16 variants and expression as MASLD progression markers.
    Hepatology. 2025;81:962-975.
    >> Share

  179. LIU LZ, Zhang Z, Zheng BH, Shi Y, et al
    Erratum: CCL15 recruits suppressive monocytes to facilitate immune escape and disease progression in hepatocellular carcinoma.
    Hepatology. 2025;81:E113-E114.
    >> Share

  180. DHANASEKARAN R, Suzuki H, Lemaitre L, Kubota N, et al
    Molecular and immune landscape of hepatocellular carcinoma to guide therapeutic decision-making.
    Hepatology. 2025;81:1038-1057.
    >> Share

    February 2025
  181. TANIAI T, Shimada S, Akiyama Y, Hatano M, et al
    Integrative transcriptome profiling elucidates molecular and immunovascular characteristics of macrotrabecular hepatocellular carcinoma.
    Hepatology. 2025 Feb 26. doi: 10.1097/HEP.0000000000001284.
    >> Share

  182. VOLKERT I, Grube J, Woitok MM, Mohamed MR, et al
    Selective genetic inactivation of Caspase 8 in hepatocytes ameliorates progression of MASH following Jnk deficiency.
    Hepatology. 2025 Feb 26. doi: 10.1097/HEP.0000000000001286.
    >> Share

  183. LIAO W, Zhang Y, Wang J, Cui G, et al
    beta-Catenin regulates distinct pathways from YAP and suppresses ONECUT1 to drive hepatoblastoma development in mice and humans.
    Hepatology. 2025 Feb 25. doi: 10.1097/HEP.0000000000001280.
    >> Share

  184. HONG L, Mei J, Sun X, Wu Y, et al
    Spatial single-cell proteomics landscape decodes the tumor microenvironmental ecosystem of intrahepatic cholangiocarcinoma.
    Hepatology. 2025 Feb 25. doi: 10.1097/HEP.0000000000001283.
    >> Share

  185. CARDOSO FS
    Letter to the Editor: Mean arterial pressure as a complex treatment target in patients with cirrhosis and acute kidney injury.
    Hepatology. 2025 Feb 25. doi: 10.1097/HEP.0000000000001288.
    >> Share

  186. TADDEI TH, Brown DB, Yarchoan M, Mendiratta-Lala M, et al
    Critical Update: AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma.
    Hepatology. 2025 Feb 24. doi: 10.1097/HEP.0000000000001269.
    >> Share

  187. WANG ZC, Gao Q, Shi JY, Guo WJ, et al
    Erratum: Protein tyrosine phosphatase receptor S acts as a metastatic suppressor in hepatocellular carcinoma by control of epithermal growth factor receptor-induced epithelial-mesenchymal transition.
    Hepatology. 2025 Feb 18. doi: 10.1097/HEP.0000000000001176.
    >> Share

  188. WONG GL, Chan HL
    Divergent trends in cirrhosis and liver cancer highlight the ongoing efforts required for hepatitis elimination.
    Hepatology. 2025 Feb 18. doi: 10.1097/HEP.0000000000001273.
    >> Share

  189. CANCADO GGL, Deeb M, Gulamhusein AF
    Liver transplantation for cholestatic liver diseases: Timing & disease recurrence.
    Hepatology. 2025 Feb 17. doi: 10.1097/HEP.0000000000001268.
    >> Share

  190. LEE EW, Saab S, Eghbalieh N, Ding PX, et al
    Coil or Plug-Assisted Retrograde transvenous obliteration (CARTO/PARTO) for treating portal hypertensive variceal bleeding: A multi-center, real-world 10-year retrospective study.
    Hepatology. 2025 Feb 5. doi: 10.1097/HEP.0000000000001255.
    >> Share

  191. SOUZA M, Al-Sharif L, Antunes VLJ, Huang DQ, et al
    Comparison of pharmacological therapies in metabolic dysfunction-associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis.
    Hepatology. 2025 Feb 4. doi: 10.1097/HEP.0000000000001254.
    >> Share

  192. BURTIS AEC, DeNicola DMC, Ferguson ME, Santos RG, et al
    Ag-driven CD8 + T cell clonal expansion is a prominent feature of MASH in humans and mice.
    Hepatology. 2025;81:591-608.
    >> Share

  193. MOGA L, Paradis V, Ferreira-Silva J, Gudavalli K, et al
    Performance of spleen stiffness measurement to rule out high-risk varices in patients with porto-sinusoidal vascular disorder.
    Hepatology. 2025;81:546-559.
    >> Share

  194. EL-SERAG HB, Jin Q, Tayob N, Salem E, et al
    HES V2.0 outperforms GALAD for detection of HCC: A phase 3 biomarker study in the United States.
    Hepatology. 2025;81:465-475.
    >> Share

  195. FEIO-AZEVEDO R, Boesch M, Radenkovic S, van Melkebeke L, et al
    Distinct immunometabolic signatures in circulating immune cells define disease outcome in acute-on-chronic liver failure.
    Hepatology. 2025;81:509-522.
    >> Share

  196. WONG YJ, Chen VL, Abdulhamid A, Tosetti G, et al
    Comparing serial and current liver stiffness measurements to predict decompensation in compensated advanced chronic liver disease patients.
    Hepatology. 2025;81:523-531.
    >> Share

  197. DUARTE-ROJO A, Taouli B, Leung DH, Levine D, et al
    Imaging-based noninvasive liver disease assessment for staging liver fibrosis in chronic liver disease: A systematic review supporting the AASLD Practice Guideline.
    Hepatology. 2025;81:725-748.
    >> Share

  198. MARINO L, Kim A, Ni B, Celi FS, et al
    Thyroid hormone action and liver disease, a complex interplay.
    Hepatology. 2025;81:651-669.
    >> Share

    January 2025
  199. ZHANG Z, Zhang Z, Zhang Y, Li Y, et al
    Phosphoproteomics delineates hepatocellular carcinoma subtypes and pinpoints therapeutic targets.
    Hepatology. 2025 Jan 31. doi: 10.1097/HEP.0000000000001250.
    >> Share

  200. LIU Q, Li J, Chen H, Song J, et al
    Letter to the Editor: Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment.
    Hepatology. 2025 Jan 31. doi: 10.1097/HEP.0000000000001215.
    >> Share

  201. YOUNOSSI ZM, de Avila L, Racila A, Nader F, et al
    Prevalence and predictors of cirrhosis and portal hypertension in the united states.
    Hepatology. 2025 Jan 29. doi: 10.1097/HEP.0000000000001243.
    >> Share

  202. CHENG K, Cai N, Yang X, Li D, et al
    Short-term starvation boosts anti-PD-L1 therapy by reshaping tumor-associated macrophages in hepatocellular carcinoma.
    Hepatology. 2025 Jan 29. doi: 10.1097/HEP.0000000000001244.
    >> Share

  203. DESPLATS V, Haudebourg L, Verger N, Assaraf J, et al
    Acute encephalopathy without hyperammonemia has a different presentation than overt hepatic encephalopathy and displays similarly severe prognosis.
    Hepatology. 2025 Jan 29. doi: 10.1097/HEP.0000000000001252.
    >> Share

  204. SEO DH, Sung PS
    Reply: Intrahepatic immunoglobulin a complex induces polarization of cancer-associated fibroblasts to matrix phenotypes in the tumor microenvironment of hepatocellular carcinoma_reply.
    Hepatology. 2025 Jan 28. doi: 10.1097/HEP.0000000000001253.
    >> Share

  205. LU Z, Wong CM
    The impact of LRP4 mutations on hepatocellular carcinoma recurrence and immunotherapy response.
    Hepatology. 2025 Jan 16. doi: 10.1097/HEP.0000000000001235.
    >> Share

  206. YANG DL, Ye L, Zeng FJ, Liu J, et al
    Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in intermedi
    Hepatology. 2025 Jan 15. doi: 10.1097/HEP.0000000000001229.
    >> Share

  207. XU E, Tabrizian P, Gutierrez J, Hoteit M, et al
    Downstaging of hepatocellular carcinoma before liver transplantation: Results from a national multi-center prospective cohort study.
    Hepatology. 2025 Jan 14. doi: 10.1097/HEP.0000000000001231.
    >> Share

  208. MA T, Bai X, Zhang Q, Chen W, et al
    Adjuvant transarterial chemoembolization for hepatocellular carcinoma following curative resection: A randomized, open-label, phase 3 trial.
    Hepatology. 2025 Jan 14. doi: 10.1097/HEP.0000000000001233.
    >> Share

  209. LIU D, Chen L, Wang Z, Li Z, et al
    Ubiquitination of TFEB increased intestinal permeability to aggravate metabolic dysfunction-associated steatohepatitis.
    Hepatology. 2025 Jan 10. doi: 10.1097/HEP.0000000000001214.
    >> Share

  210. OBRADOVIC F, Vitello DJ, Hasjim BJ, Obayemi J, et al
    Comparing the cost of cirrhosis to other common chronic diseases: A longitudinal study in a large national insurance database.
    Hepatology. 2025 Jan 6. doi: 10.1097/HEP.0000000000001206.
    >> Share

  211. ROCCARINA D, Saltini D, Adotti V, Rosi M, et al
    End-procedural adherence to recommended hemodynamic targets does not improve the outcome of elective tips in cirrhotic patients.
    Hepatology. 2025 Jan 3. doi: 10.1097/HEP.0000000000001224.
    >> Share

  212. KABELITZ MA, Hartl L, Schaub G, Tiede A, et al
    Identification of optimal portal pressure decrease to control ascites while minimizing hepatic encephalopathy after TIPS: A multicenter study.
    Hepatology. 2025 Jan 3. doi: 10.1097/HEP.0000000000001219.
    >> Share

  213. RONCA V, Davies SP, Oo YH, Lleo A, et al
    The immunological landscape of primary biliary cholangitis: Mechanisms and therapeutic prospects.
    Hepatology. 2025 Jan 3. doi: 10.1097/HEP.0000000000001225.
    >> Share

  214. KWAK M, Kim HS, Jiang ZG, Yeo YH, et al
    MASLD/MetALD and mortality in individuals with any cardio-metabolic risk factor: A population-based study with 26.7 years of follow-up.
    Hepatology. 2025;81:228-237.
    >> Share

  215. HOBEIKA C, Ronot M, Guiu B, Ferraioli G, et al
    Ultrasound-based steatosis grading system using 2D-attenuation imaging: An individual patient data meta-analysis with external validation.
    Hepatology. 2025;81:212-227.
    >> Share

  216. KE C, Xiao C, Li J, Wu X, et al
    FMO2 ameliorates nonalcoholic fatty liver disease by suppressing ER-to-Golgi transport of SREBP1.
    Hepatology. 2025;81:181-197.
    >> Share


  217. Erratum: Expression and functional significance of Twist1 in hepatocellular carcinoma: Its role in vasculogenic mimicry.
    Hepatology. 2025;81:E26-E27.
    >> Share

  218. WILECHANSKY RM
    Putting mean arterial pressure on the map as an AKI biomarker in cirrhosis.
    Hepatology. 2025;81:3-4.
    >> Share

    December 2024
  219. CELSA C, Cabibbo G, Pinato DJ
    Reply: Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment.
    Hepatology. 2024 Dec 25. doi: 10.1097/HEP.0000000000001217.
    >> Share

  220. SUN R, Liu K, Pan S, Ye Y, et al
    LRP4 mutations promote tumour progression and resistance to anti-PD-1 therapy in recurrent hepatocellular carcinoma.
    Hepatology. 2024 Dec 24. doi: 10.1097/HEP.0000000000001212.
    >> Share

  221. MA S, Chen J, Li J
    Letter to the editor: Intrahepatic immunoglobulin A complex induces polarization of cancer-associated fibroblasts to matrix phenotypes in the tumor microenvironment of hepatocellular carcinoma.
    Hepatology. 2024 Dec 23. doi: 10.1097/HEP.0000000000001197.
    >> Share

  222. TAO J, Wu Z, Liang Y, Wang J, et al
    Lhx2 specifically expressed in hepatic stellate cells promotes liver regeneration and inhibits liver fibrosis.
    Hepatology. 2024 Dec 18. doi: 10.1097/HEP.0000000000001201.
    >> Share

  223. VUTIEN P, Barnard Giustini A, Kim NJ, Moon AM, et al
    Validation and expansion of Baveno VII criteria for cACLD and CSPH based on liver stiffness and platelet count: Correlation with risk of hepatic decompensation and death.
    Hepatology. 2024 Dec 17. doi: 10.1097/HEP.0000000000001183.
    >> Share

  224. YANG Y, Ni Q, Li H, Sun J, et al
    Genomic and the tumor microenvironment heterogeneity in multifocal hepatocellular carcinoma.
    Hepatology. 2024 Dec 12. doi: 10.1097/HEP.0000000000001191.
    >> Share

  225. ZHOU KQ, Zhong YC, Song MF, Sun YF, et al
    Distinct immune microenvironment of venous tumor thrombus in hepatocellular carcinoma at single-cell resolution.
    Hepatology. 2024 Dec 10. doi: 10.1097/HEP.0000000000001182.
    >> Share

  226. CONDE DE LA ROSA L, Fabrega L, Torres S, Nunez S, et al
    Stard1 promotes cholestatic liver injury and disease progression by sensitizing to bile acid hepatotoxicity.
    Hepatology. 2024 Dec 9. doi: 10.1097/HEP.0000000000001184.
    >> Share

  227. GONZALEZ-RECIO I, Goikoetxea-Usandizaga N, Rejano-Gordillo CM, Conter C, et al
    Modulatory effects of CNNM4 on Protein-L-Isoaspartyl-O-Methyltransferase repair function during Alcohol-Induced hepatic damage.
    Hepatology. 2024 Dec 6. doi: 10.1097/HEP.0000000000001156.
    >> Share

  228. BROOKHART MA, Mayne TJ, Coombs C, Breskin A, et al
    Hepatic real-world outcomes with obeticholic acid in primary biliary cholangitis (HEROES): A trial emulation study design.
    Hepatology. 2024 Dec 2. doi: 10.1097/HEP.0000000000001174.
    >> Share

  229. HUI RW, Chiu KW, Lee IC, Wang C, et al
    Multimodal multiphasic pre-operative image-based deep-learning predicts hepatocellular carcinoma outcomes after curative surgery.
    Hepatology. 2024 Dec 2. doi: 10.1097/HEP.0000000000001180.
    >> Share

  230. SENGUPTA S, Gill V, Mellinger JL
    Alcohol-associated liver disease and public health policies.
    Hepatology. 2024;80:1323-1341.
    >> Share

  231. HAQUE LY, Leggio L
    Integrated and collaborative care across the spectrum of alcohol-associated liver disease and alcohol use disorder.
    Hepatology. 2024;80:1408-1423.
    >> Share

  232. MAREK GW, Malhi H
    MetALD: Does it require a different therapeutic option?
    Hepatology. 2024;80:1424-1440.
    >> Share

  233. NARAYANAN P, Wu T, Shah VH, Curtis BL, et al
    Insights into ALD and AUD diagnosis and prognosis: Exploring AI and multimodal data streams.
    Hepatology. 2024;80:1480-1494.
    >> Share

  234. RAYA TONETTI F, Eguileor A, Mrdjen M, Pathak V, et al
    Gut-liver axis: Recent concepts in pathophysiology in alcohol-associated liver disease.
    Hepatology. 2024;80:1342-1371.
    >> Share

  235. ABERG F, Jiang ZG, Cortez-Pinto H, Mannisto V, et al
    Alcohol-associated liver disease-Global epidemiology.
    Hepatology. 2024;80:1307-1322.
    >> Share

  236. FU Y, Maccioni L, Wang XW, Greten TF, et al
    Alcohol-associated liver cancer.
    Hepatology. 2024;80:1462-1479.
    >> Share

  237. ISRAELSEN M, Rungratanawanich W, Thiele M, Liangpunsakul S, et al
    Non-invasive tests for alcohol-associated liver disease.
    Hepatology. 2024;80:1390-1407.
    >> Share

    November 2024
  238. VERCHER E, Covo-Vergara A, Conde E, Hernandez-Rueda M, et al
    Human T cells engineered with an HLA-A2-restricted murine T-cell receptor targeting Glypican 3 effectively control human hepatocellular carcinoma in mice.
    Hepatology. 2024 Nov 26. doi: 10.1097/HEP.0000000000001175.
    >> Share

  239. HAN J, Shan D
    Letter to the Editor: Refining the role of HAF in hepatocellular carcinoma.
    Hepatology. 2024 Nov 21. doi: 10.1097/HEP.0000000000001171.
    >> Share

  240. SCHEINER B, Kang B, Balcar L, Radu IP, et al
    Outcome and management of patients with hepatocellular carcinoma who achieved a complete response to immunotherapy-based systemic therapy.
    Hepatology. 2024 Nov 21. doi: 10.1097/HEP.0000000000001163.
    >> Share

  241. SUMMERS SA, Koh MY
    Reply: Refining the role of HAF in hepatocellular carcinoma.
    Hepatology. 2024 Nov 21. doi: 10.1097/HEP.0000000000001173.
    >> Share

  242. WONG YJ, Teng M, Sim A, Abraldes JG, et al
    Reply: Quality indicators and the safety profile of endoscopic intervention in patients with bleeding esophageal varices.
    Hepatology. 2024 Nov 12. doi: 10.1097/HEP.0000000000001155.
    >> Share

  243. LEVY C, Bowlus CL
    Primary Biliary Cholangitis: personalizing second-line therapies.
    Hepatology. 2024 Nov 12. doi: 10.1097/HEP.0000000000001166.
    >> Share

  244. JOHN BV, Bastaich D, Dahman B
    Reply: Association of hepatitis delta virus infection and hepatocellular carcinoma, hepatic decompensation, all-cause and liver-related death in a national cohort.
    Hepatology. 2024 Nov 11. doi: 10.1097/HEP.0000000000001162.
    >> Share

  245. KRIGE JE, Jonas EG, Bernon MM
    Letter to the editor: Quality indicators and the safety profile of endoscopic intervention in patients with bleeding esophageal varices.
    Hepatology. 2024 Nov 11. doi: 10.1097/HEP.0000000000001153.
    >> Share

  246. HE Z, Wang C, Tian H
    Letter to the editor : Association of hepatitis delta virus infection and hepatocellular carcinoma, hepatic decompensation, all-cause and liver-related death in a national cohort.
    Hepatology. 2024 Nov 11. doi: 10.1097/HEP.0000000000001159.
    >> Share

  247. BRUNO BJ, Weavil JC, Ogle J, Chidambaram N, et al
    Oral LPCN 1148 improves sarcopenia and hepatic encephalopathy in male patients with cirrhosis: A randomized, placebo-controlled phase 2 trial.
    Hepatology. 2024 Nov 8. doi: 10.1097/HEP.0000000000001146.
    >> Share

  248. LI S, Wu Z
    Letter to the Editor: Enhancing automated speech analysis for hepatic encephalopathy detection.
    Hepatology. 2024 Nov 7. doi: 10.1097/HEP.0000000000001150.
    >> Share

  249. LIAO TL, Chen DY, Hsieh SL, Yang YY, et al
    Platelet-derived mitochondria regulate lipid metabolism in nonalcoholic steatohepatitis via extracellular vesicles.
    Hepatology. 2024 Nov 7. doi: 10.1097/HEP.0000000000001149.
    >> Share

  250. ALVARADO-TAPIAS E, Brujats A, Puente A, Ardevol A, et al
    Hemodynamic effects of carvedilol plus simvastatin in cirrhosis with severe portal hypertension and suboptimal response to beta-blockers: A double-blind, placebo-controlled, randomized-trial.
    Hepatology. 2024 Nov 7. doi: 10.1097/HEP.0000000000001148.
    >> Share

  251. BLOOM PP, Lok AS
    Reply: Enhancing automated speech analysis for hepatic encephalopathy detection.
    Hepatology. 2024 Nov 7. doi: 10.1097/HEP.0000000000001151.
    >> Share

  252. CHARU V, Liang JW, Mannalithara A, Kwong A, et al
    Benchmarking clinical risk prediction algorithms with ensemble machine learning for the noninvasive diagnosis of liver fibrosis in NAFLD.
    Hepatology. 2024;80:1184-1195.
    >> Share

  253. CHALASANI N, Vilar-Gomez E, Loomba R, Yates KP, et al
    PNPLA3 rs738409, age, diabetes, sex, and advanced fibrosis jointly contribute to the risk of major adverse liver outcomes in metabolic dysfunction-associated steatotic liver disease.
    Hepatology. 2024;80:1212-1226.
    >> Share

  254. STONEBRAKER JR, Pace RG, Gallins PJ, Dang H, et al
    Genetic variation in severe cystic fibrosis liver disease is associated with novel mechanisms for disease pathogenesis.
    Hepatology. 2024;80:1012-1025.
    >> Share

  255. GE J, Sun S, Owens J, Galvez V, et al
    Development of a liver disease-specific large language model chat interface using retrieval-augmented generation.
    Hepatology. 2024;80:1158-1168.
    >> Share

  256. ZHANG L, Jiao K, Liu Y, Xu G, et al
    UBXN9 inhibits the RNA exosome function to promote T cell control of liver tumorigenesis.
    Hepatology. 2024;80:1041-1057.
    >> Share

  257. GAO W, Zhang L, Li Z, Wu T, et al
    Nuclear Acly protects the liver from ischemia-reperfusion injury.
    Hepatology. 2024;80:1087-1103.
    >> Share


  258. Erratum: NK-cell-elicited gasdermin-D-dependent hepatocyte pyroptosis induces neutrophil extracellular traps that facilitates HBV-related acute-on-chronic liver failure.
    Hepatology. 2024;80:E92.
    >> Share


  259. Erratum: Basolateral CD147 induces hepatocyte polarity loss by E-cadherin ubiquitination and degradation in hepatocellular carcinoma progress.
    Hepatology. 2024;80:E91.
    >> Share


  260. Erratum: Diagnosis, Evaluation, and Management of Ascites and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases.
    Hepatology. 2024;80:E89.
    >> Share

  261. NARAYANAN P
    PAR for the liver course: Preserving platelet function mitigates outcomes in cirrhosis.
    Hepatology. 2024;80:991-992.
    >> Share

    October 2024
  262. FAN G, Tao C, Li L, Xie T, et al
    The co-location of MARCO+ tumor-associated macrophages and CTSE+ tumor cells determined the poor prognosis in intrahepatic cholangiocarcinoma.
    Hepatology. 2024 Oct 29. doi: 10.1097/HEP.0000000000001138.
    >> Share

  263. VONADA A, Grompe M
    In vivo selection of hepatocytes.
    Hepatology. 2024 Oct 29. doi: 10.1097/HEP.0000000000001143.
    >> Share

  264. CIRIA R, Ivanics T, Aliseda D, Claasen M, et al
    Liver transplantation for primary and secondary liver tumours. patient-level meta-analyses compared to unos conventional indications.
    Hepatology. 2024 Oct 28. doi: 10.1097/HEP.0000000000001129.
    >> Share

  265. KIM JW, Tung HC, Ke M, Xu P, et al
    The de-sulfinylation enzyme sulfiredoxin-1 attenuates hepatic stellate cell activation and liver fibrosis by modulating the PTPN12-NLRP3 axis.
    Hepatology. 2024 Oct 24. doi: 10.1097/HEP.0000000000001133.
    >> Share

  266. ZHOU K, Wang Z, Guo W, Xie F, et al
    Unraveling bidirectional evolution of unstable mitochondrial DNA mutations in hepatocellular carcinoma at single-cell resolution.
    Hepatology. 2024 Oct 11. doi: 10.1097/HEP.0000000000001113.
    >> Share

  267. KEZER CA, Berzigotti A, Fortune BE, Simonetto DA, et al
    Drug treatments to prevent first decompensation in cirrhosis.
    Hepatology. 2024 Oct 8. doi: 10.1097/HEP.0000000000001117.
    >> Share

  268. FAR A, Bastani A, Lee A, Gologorskaya O, et al
    Evaluating the positive predictive value of code-based identification of cirrhosis and its complications utilizing GPT-4.
    Hepatology. 2024 Oct 8. doi: 10.1097/HEP.0000000000001115.
    >> Share

  269. NAKAGAWA H
    New ubiquitomic subtypes in hepatocellular carcinoma: Insights for future therapeutic approaches.
    Hepatology. 2024 Oct 7. doi: 10.1097/HEP.0000000000001116.
    >> Share

  270. GIRI N, Niewisch MR, Rosenberg PS, Vittal A, et al
    Reply: Accurate predictor for liver disease progression in patients with DC/TBD.
    Hepatology. 2024;80:E61-E62.
    >> Share

  271. ZHAO J, Bi Y
    Letter to the Editor: Accurate predictor for liver disease progression in patients with DC/TBD.
    Hepatology. 2024;80:E60.
    >> Share

  272. EL-SHABRAWI MHF, Elamin A, Kamal NM
    Letter to the Editor: MAFLD versus MASLD criteria debate- Certainly not for children!
    Hepatology. 2024;80:E55-E56.
    >> Share

  273. LA VECCHIA C, Santucci C
    Liver cancer in young adults: Validity of global data sets.
    Hepatology. 2024;80:766-769.
    >> Share

  274. DANPANICHKUL P, Aboona MB, Sukphutanan B, Kongarin S, et al
    Incidence of liver cancer in young adults according to the Global Burden of Disease database 2019.
    Hepatology. 2024;80:828-843.
    >> Share

  275. CHEUNG KS, Ng HY, Hui RWH, Lam LK, et al
    Effects of empagliflozin on liver fat in patients with metabolic dysfunction-associated steatotic liver disease without diabetes mellitus: A randomized, double-blind, placebo-controlled trial.
    Hepatology. 2024;80:916-927.
    >> Share

  276. TANG S, Borlak J
    Genomics of human NAFLD: Lack of data reproducibility and high interpatient variability in drug target expression as major causes of drug failures.
    Hepatology. 2024;80:901-915.
    >> Share

  277. SU GL, Zhang P, Belancourt PX, Youles B, et al
    Incorporation of quantitative imaging data using artificial intelligence improves risk prediction in veterans with liver disease.
    Hepatology. 2024;80:928-936.
    >> Share

  278. PENRICE DD, Jalan-Sakrikar N, Jurk D, Passos JF, et al
    Telomere dysfunction in chronic liver disease: The link from aging.
    Hepatology. 2024;80:951-964.
    >> Share

  279. SAMPLE JW
    Beyond monotherapy: Combining radiotherapy with sintilimab and bevacizumab for hepatocellular carcinoma with portal vein tumor thrombus.
    Hepatology. 2024;80:757-758.
    >> Share

    September 2024
  280. LIN XT, Luo YD, Mao C, Gong Y, et al
    Integrated ubiquitomics characterization of hepatocellular carcinomas.
    Hepatology. 2024 Sep 30. doi: 10.1097/HEP.0000000000001096.
    >> Share

  281. KODAMA T
    Geographical and molecular disparity of HBV integration: Implications for hepatocarcinogenesis and clinical outcomes in HCC.
    Hepatology. 2024 Sep 30. doi: 10.1097/HEP.0000000000001111.
    >> Share

  282. NOUREDDIN M, Truong E, Mayo R, Martinez-Arranz I, et al
    Letter to the Editor: Serum identification of At-Risk MASH: The metabolomics-advanced steatohepatitis fibrosis score (MASEF).
    Hepatology. 2024 Sep 26. doi: 10.1097/HEP.0000000000001061.
    >> Share

  283. AJOUAOU Y, Sadler KC
    Uncovering epigenetic heterogeneity in hepatocellular carcinoma.
    Hepatology. 2024 Sep 18. doi: 10.1097/HEP.0000000000001097.
    >> Share

  284. LYU X, Sze KM, Lee JM, Husain A, et al
    Disparity landscapes of viral-induced structural variations in hepatocellular carcinoma: Mechanistic characterization and functional implications.
    Hepatology. 2024 Sep 13. doi: 10.1097/HEP.0000000000001087.
    >> Share

  285. BLOOM PP, Fisher CJ, Tedesco N, Kamdar N, et al
    HEAR-MHE study: Automated speech analysis identifies minimal hepatic encephalopathy and may predict future overt hepatic encephalopathy.
    Hepatology. 2024 Sep 12. doi: 10.1097/HEP.0000000000001086.
    >> Share

  286. ACUNA-PILARTE K, Reichert EC, Song Green Y, Halberg LM, et al
    HAF prevents hepatocyte apoptosis and progression to MASH and hepatocellular carcinoma through transcriptional regulation of the NF-kappaB pathway.
    Hepatology. 2024 Sep 10. doi: 10.1097/HEP.0000000000001070.
    >> Share

  287. JOHN BV, Bastaich D, Amoli MM, Wong RJ, et al
    Association of hepatitis delta virus infection and hepatocellular carcinoma, hepatic decompensation, all-cause and liver-related death in a national cohort.
    Hepatology. 2024 Sep 10. doi: 10.1097/HEP.0000000000001092.
    >> Share

  288. YOUNOSSI ZM, Stepanova M, Racila A, Henry L, et al
    Health-Related quality of life (HRQL) assessments in a 52-Week, Double-Blind, randomized, Placebo-Controlled phase 3 study of resmetirom (MGL-3196) in patients with metabolic dysfunction associated steatohepatitis (MASH) and fibrosis.
    Hepatology. 2024 Sep 6. doi: 10.1097/HEP.0000000000001084.
    >> Share

  289. WU Y, Li L, Li W, Li N, et al
    Stretch-induced hepatic endothelial mechanocrine promotes hepatocyte proliferation.
    Hepatology. 2024 Sep 6. doi: 10.1097/HEP.0000000000001082.
    >> Share


  290. Hepatology Highlights.
    Hepatology. 2024;80:501-502.
    >> Share

  291. VILLANI R, Serviddio G
    Letter to the Editor: Multifactorial steatotic liver disease: A new entity to be included in new international classification of liver steatosis.
    Hepatology. 2024;80:E40-E41.
    >> Share

  292. ALBORAIE M, Fouad Y, Eslam M
    Letter to the Editor: MAFLD versus MASLD-Which is more appropriate from a global perspective?
    Hepatology. 2024;80:E42-E43.
    >> Share

  293. CHUNG SW, Moon HS, Shin H, Han H, et al
    Inhibition of sodium-glucose cotransporter-2 and liver-related complications in individuals with diabetes: a Mendelian randomization and population-based cohort study.
    Hepatology. 2024;80:633-648.
    >> Share

  294. TERBAH R, Testro AG, Hoermann R, Majumdar A, et al
    Continuous home terlipressin infusion increases handgrip strength and reduces ascites-A prospective randomized crossover study.
    Hepatology. 2024;80:605-620.
    >> Share

  295. WATLING CZ, Wojt A, Florio AA, Butera G, et al
    Fiber and whole grain intakes in relation to liver cancer risk: An analysis in 2 prospective cohorts and systematic review and meta-analysis of prospective studies.
    Hepatology. 2024;80:552-565.
    >> Share

  296. LIN P, Yan X, Jing S, Wu Y, et al
    Single-cell and spatially resolved transcriptomics for liver biology.
    Hepatology. 2024;80:698-720.
    >> Share


  297. Hepatology Highlights.
    Hepatology. 2024;80:501-502.
    >> Share

    August 2024
  298. FACCIOLI LA, Sun Y, Animasahun O, Motomura T, et al
    Human induced pluripotent stem cell based hepatic-modeling of lipid metabolism associated TM6SF2 E167K variant.
    Hepatology. 2024 Aug 27. doi: 10.1097/HEP.0000000000001065.
    >> Share

  299. LUCAS MR, Pilling LC, Atkins JL, Melzer D, et al
    Incidence of liver complications with hemochromatosis associated HFE p.C282Y homozygosity: The role of central adiposity.
    Hepatology. 2024 Aug 23. doi: 10.1097/HEP.0000000000001056.
    >> Share

  300. VAN DER MEER AJ, Sonneveld MJ
    Towards risk-based surveillance for hepatocellular carcinoma after HCV cure?
    Hepatology. 2024 Aug 13. doi: 10.1097/HEP.0000000000001057.
    >> Share

  301. LIM HY, Heo J, Peguero JA, Ryoo BY, et al
    Efficacy and safety of bintrafusp alfa in two phase 1 expansion cohorts with advanced hepatocellular carcinoma.
    Hepatology. 2024 Aug 13. doi: 10.1097/HEP.0000000000001054.
    >> Share

  302. BJORNSSON ES, Devarbhavi HC
    Drug induced cholestatic liver diseases.
    Hepatology. 2024 Aug 8. doi: 10.1097/HEP.0000000000001052.
    >> Share

  303. SHANG Y, Akbari C, Dodd M, Zhang X, et al
    Association between longitudinal biomarkers and major adverse liver outcomes in patients with non-cirrhotic metabolic dysfunction-associated steatotic liver disease.
    Hepatology. 2024 Aug 7. doi: 10.1097/HEP.0000000000001045.
    >> Share

  304. NAULT JC, Iavarone M
    Management of patients with advanced hepatocellular carcinoma receiving atezolizumab/bevacizumab: Take care of cirrhosis!
    Hepatology. 2024 Aug 5. doi: 10.1097/HEP.0000000000001047.
    >> Share


  305. Hepatology Highlights.
    Hepatology. 2024;80:255-256.
    >> Share

  306. GARCIA-TSAO G, Kaplan DE
    Reply: Endoscopy for potential variceal bleeding within 12 hours-Not so fast!
    Hepatology. 2024;80:E36.
    >> Share

  307. RAMAN KP, Patch D
    Tranexamic acid in variceal bleeding revisited.
    Hepatology. 2024;80:257-259.
    >> Share

  308. JEPSEN P, West J, Kann AE, Kraglund F, et al
    Risk of alcohol-associated liver disease in the offspring of parents with alcohol-associated liver disease: A nationwide cohort study.
    Hepatology. 2024;80:418-427.
    >> Share

  309. WANG Q, Bu Q, Pan B, Yin Y, et al
    Letter to the Editor: Scavenger receptor a is a major homeostatic regulator that restrains drug-induced liver injury.
    Hepatology. 2024;80:E24-E25.
    >> Share

  310. YANG D, Tian T, Li X, Zhang B, et al
    ZNT1 and Zn 2+ control TLR4 and PD-L1 endocytosis in macrophages to improve chemotherapy efficacy against liver tumor.
    Hepatology. 2024;80:312-329.
    >> Share

  311. HLADY RA, Robertson KD
    Epigenetic memory of environmental exposures as a mediator of liver disease.
    Hepatology. 2024;80:451-464.
    >> Share

    July 2024
  312. LIM N, Devuni D, German M, Guy J, et al
    The rise of multidisciplinary clinics in hepatology: A practical, how-to-guide, and review of the literature.
    Hepatology. 2024 Jul 30. doi: 10.1097/HEP.0000000000001036.
    >> Share

  313. WANG X, Liu Y, Zhang S, Zhang J, et al
    Genomic and transcriptomic analyses of chemical hepatocarcinogenesis aggravated by oncoprotein loss.
    Hepatology. 2024 Jul 30. doi: 10.1097/HEP.0000000000001037.
    >> Share

  314. WANG M, Chiou SH, Ganger D, Ruck J, et al
    Liver transplantation provides survival benefit at all levels of frailty: From the Multicenter Functional Assessment in Liver Transplantation Study.
    Hepatology. 2024 Jul 24. doi: 10.1097/HEP.0000000000001030.
    >> Share

  315. JEONG JM, Choi SE, Shim YR, Kim HH, et al
    CX3CR1+ macrophages interact with hepatic stellate cells to promote hepatocellular carcinoma through CD8+ T cell suppression.
    Hepatology. 2024 Jul 19. doi: 10.1097/HEP.0000000000001021.
    >> Share

  316. CELSA C, Cabibbo G, Fulgenzi CAM, Battaglia S, et al
    Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment.
    Hepatology. 2024 Jul 19. doi: 10.1097/HEP.0000000000001026.
    >> Share


  317. Diagnosis and Management of Hepatocellular Carcinoma.
    Hepatology. 2024 Jul 17. doi: 10.1097/HEP.0000000000001010.
    >> Share

  318. ZHANG L, Xie P, Li M, Zhang X, et al
    Hepatic GDP-fucose transporter SLC35C1 attenuates cholestatic liver injury and inflammation by inducing CEACAM1 N153 fucosylation.
    Hepatology. 2024 Jul 10. doi: 10.1097/HEP.0000000000001003.
    >> Share

  319. HUANG Y, Yu F, Ding Y, Zhang H, et al
    Hepatic IL22RA1 deficiency promotes hepatic steatosis by modulating oxysterol in the liver.
    Hepatology. 2024 Jul 10. doi: 10.1097/HEP.0000000000000998.
    >> Share

  320. HOOVER JM
    Letter to the Editor: Utilization of beta blockers in patients with portal hypertension and peripheral artery disease.
    Hepatology. 2024 Jul 8. doi: 10.1097/HEP.0000000000001008.
    >> Share

  321. KENT D, Ng SS, Syanda AM, Khoshkenar P, et al
    Reduction of Z alpha-1 antitrypsin polymers in human iPSC-hepatocytes and mice by LRRK2 inhibitors.
    Hepatology. 2024 Jul 2. doi: 10.1097/HEP.0000000000000969.
    >> Share


  322. Erratum: A prognostic strategy based on stage of cirrhosis and HVPG to improve risk stratification after variceal bleeding.
    Hepatology. 2024;80:E23.
    >> Share


  323. Hepatology Highlights.
    Hepatology. 2024;80:1-2.
    >> Share

  324. LAINE L, Barkun AN, Leontiadis GI
    Letter to the Editor: Endoscopy for potential variceal bleeding within 12 hours-Not so fast!
    Hepatology. 2024;80:E15-E16.
    >> Share

  325. KRAWCZYK M, Lammert F
    Letter to the Editor: NAFLD vs. MASLD-There ain't no such thing as a free lunch.
    Hepatology. 2024;80:E11-E12.
    >> Share

  326. RINELLA ME, Lazarus JV, Newsome PN
    Reply: NAFLD vs. MASLD-There ain't no such thing as a free lunch.
    Hepatology. 2024;80:E13-E14.
    >> Share

  327. MA J, Liangpunsakul S
    Solving the puzzle of fibrosis resolution in alcohol-associated liver disease: An insight from KDM5 demethylases and LXR activation.
    Hepatology. 2024;80:14-17.
    >> Share

  328. DAVENPORT M
    Serum matrix metalloproteinase-7 (MMP-7): As good as it gets?
    Hepatology. 2024;80:18-19.
    >> Share

  329. WOLTERS F, Oude Elferink RPJ, Beuers U
    PPARalpha, PPARdelta, or both-that is the question!
    Hepatology. 2024;80:8-10.
    >> Share

  330. KOSHIOL J, Krawczyk M
    enHanCCing knowledge of genetic factors in primary liver tumor.
    Hepatology. 2024;80:11-13.
    >> Share

  331. NEIL DAH, Smith ML, Minervini M, Demetris AJ, et al
    Reply: Additional viewpoints from transplant surgeons on Banff consensus recommendations for the assessment of steatotic donor livers.
    Hepatology. 2024;80:E6-E7.
    >> Share

  332. CAO H, Gu J
    Letter to the Editor: Additional viewpoints from transplant surgeons on Banff consensus recommendations for the assessment of steatotic donor livers.
    Hepatology. 2024;80:E4-E5.
    >> Share

  333. ABERG F, Asteljoki J, Mannisto V, Luukkonen PK, et al
    Combined use of the CLivD score and FIB-4 for prediction of liver-related outcomes in the population.
    Hepatology. 2024;80:163-172.
    >> Share

  334. FLORIS A, Chandla S, Lim Y, Barbier-Torres L, et al
    Sumoylation of methionine adenosyltransferase alpha 1 promotes mitochondrial dysfunction in alcohol-associated liver disease.
    Hepatology. 2024;80:102-118.
    >> Share

  335. LOPEZ-PASCUAL A
    Navigating liver disease complexity: Innovations in in vitro modeling and precision medicine.
    Hepatology. 2024;80:20-23.
    >> Share

  336. SCHONFELD M, O'Neil M, Weinman SA, Tikhanovich I, et al
    Alcohol-induced epigenetic changes prevent fibrosis resolution after alcohol cessation in miceresolution.
    Hepatology. 2024;80:119-135.
    >> Share

  337. TONG Y, Wang F, Li S, Guo W, et al
    Histone methyltransferase KMT5C drives liver cancer progression and directs therapeutic response to PARP inhibitors.
    Hepatology. 2024;80:38-54.
    >> Share

  338. SINGAL AK, Shah VH, Malhi H
    Emerging targets for therapy in ALD: Lessons from NASH.
    Hepatology. 2024;80:223-237.
    >> Share


  339. Erratum: c-Jun mediates hepatitis C virus hepatocarcinogenesis through signal transducer and activator of transcription 3 and nitric oxide-dependent impairment of oxidative DNA repair.
    Hepatology. 2024;80:E21.
    >> Share

  340. PREMKUMAR M, Karvellas CJ, Kulkarni AV, Bhujade H, et al
    Role of Point-of-Care ultrasound (POCUS) in clinical hepatology.
    Hepatology. 2024 Jul 1. doi: 10.1097/HEP.0000000000000990.
    >> Share

    June 2024
  341. GAO D, Ping Yam JW
    Reversal of lipid metabolism as a therapeutic approach for hepatocellular carcinoma.
    Hepatology. 2024 Jun 27. doi: 10.1097/HEP.0000000000001000.
    >> Share

  342. PREMKUMAR M, Kulkarni A, Izzy M
    'Regarding Evaluation of terlipressin-related patient outcomes in hepatorenal syndrome-acute kidney injury using point-of-care echocardiography'.
    Hepatology. 2024 Jun 26. doi: 10.1097/HEP.0000000000000988.
    >> Share

  343. LUO X, Yu J
    Regarding terlipressin-related patient outcomes in hepatorenal syndrome-acute kidney injury.
    Hepatology. 2024 Jun 25. doi: 10.1097/HEP.0000000000000984.
    >> Share

  344. RATZIU V, Yilmaz Y, Lazas D, Friedman SL, et al
    Aramchol improves hepatic fibrosis in MASH: Results of multimodality assessment using both conventional and digital pathology.
    Hepatology. 2024 Jun 25. doi: 10.1097/HEP.0000000000000980.
    >> Share

  345. KANG K, Wu Y
    Letter to the Editor: Regarding the use of decision curve analysis in predicting long-term complications of liver cirrhosis.
    Hepatology. 2024 Jun 21. doi: 10.1097/HEP.0000000000000945.
    >> Share

  346. LI J, Ma X, Xuan Q, Li Q, et al
    Modulation of monocyte activity by hepatocellular MicroRNA delivery via hepatitis B virus surface antigen particles: Implications for pathobiology of chronic hepatitis B.
    Hepatology. 2024 Jun 20. doi: 10.1097/HEP.0000000000000972.
    >> Share

  347. YANG M, Song X, Zhang F, Li M, et al
    Spatial proteomic landscape of primary and relapsed hepatocellular carcinoma reveals immune escape characteristics in early relapse.
    Hepatology. 2024 Jun 20. doi: 10.1097/HEP.0000000000000979.
    >> Share

  348. BERENGUER J, Bellon JM, Banares R, Gonzalez-Garcia J, et al
    Reply: Clinical outcomes and prognostic factors after HCV clearance with DAA in HIV/HCV-coinfected patients with advanced fibrosis/cirrhosis.
    Hepatology. 2024 Jun 20. doi: 10.1097/HEP.0000000000000977.
    >> Share

  349. LIU Q, Zhang X, Qi J, Tian X, et al
    Comprehensive profiling of lipid metabolic reprogramming expands precision medicine for hepatocellular carcinoma.
    Hepatology. 2024 Jun 19. doi: 10.1097/HEP.0000000000000962.
    >> Share

  350. SIMONETTO DA, Winder GS, Connor AA, Terrault NA, et al
    Liver transplantation for Alcohol-associated liver disease.
    Hepatology. 2024 Jun 18. doi: 10.1097/HEP.0000000000000978.
    >> Share


  351. Process Measures to Improve Outcomes During Peri-Procedure Management of Coagulopathy in Cirrhosis.
    Hepatology. 2024 Jun 17. doi: 10.1097/HEP.0000000000000964.
    >> Share

  352. HUANG L, Zou L
    Letter to the Editor: Clinical outcomes and prognostic factors after HCV clearance with DAA in HIV/HCV-coinfected patients with advanced fibrosis/cirrhosis.
    Hepatology. 2024 Jun 17. doi: 10.1097/HEP.0000000000000974.
    >> Share


  353. Erratum: Interleukin-22 promotes human hepatocellular carcinoma by activation of STAT3.
    Hepatology. 2024;79:E171-E172.
    >> Share


  354. Hepatology Highlights.
    Hepatology. 2024;79:1239-1240.
    >> Share

  355. LI Z, Zhang Y, Li Y, Lan J, et al
    Letter to the Editor: Statins as potential confounding factors to investigate the association between the use of GLP-1 receptor agonists and risk of HCC.
    Hepatology. 2024;79:E169-E170.
    >> Share

  356. LOMBARDI R, Dalbeni A, Mantovani A, Ravaioli F, et al
    Reply: AGILE 3+ score, enhancing the diagnostic accuracy of advanced fibrosis in patients with nonalcoholic fatty liver disease.
    Hepatology. 2024;79:E155-E156.
    >> Share

  357. CALZADILLA-BERTOT L, Jeffrey AW, Jeffrey GP
    Letter to the Editor: AGILE 3+ score, enhancing the diagnostic accuracy of advanced fibrosis in patients with nonalcoholic fatty liver disease.
    Hepatology. 2024;79:E153-E154.
    >> Share

  358. YEH JG, Newsome PN
    Association of glucagon-like peptide-1 receptor agonists with serious liver events among patients with type 2 diabetes: A Scandinavian cohort study.
    Hepatology. 2024;79:1255-1257.
    >> Share

  359. HANSEN BE, Vandriel SM, Vig P, Garner W, et al
    Event-free survival of maralixibat-treated patients with Alagille syndrome compared to a real-world cohort from GALA.
    Hepatology. 2024;79:1279-1292.
    >> Share

  360. ABDELMALEK MF, Rinella ME
    Steatotic liver disease, a useful construct in primary care that doesn't upset the apple cart.
    Hepatology. 2024;79:1252-1254.
    >> Share

  361. ENGSTROM A, Wintzell V, Melbye M, Svanstrom H, et al
    Association of glucagon-like peptide-1 receptor agonists with serious liver events among patients with type 2 diabetes: A Scandinavian cohort study.
    Hepatology. 2024;79:1401-1411.
    >> Share

  362. ZHAO G, Ma Q, Yang H, Jiang H, et al
    Base editing of the mutated TERT promoter inhibits liver tumor growth.
    Hepatology. 2024;79:1310-1323.
    >> Share

  363. SCHMIDT KA, Simonetto DA
    The telomere tango: Liver disease in the genomic spotlight.
    Hepatology. 2024;79:1249-1251.
    >> Share

  364. SIDALI S, Borie R, Sicre de Fontbrune F, El Husseini K, et al
    Liver disease in germline mutations of telomere-related genes: Prevalence, clinical, radiological, pathological features, outcome, and risk factors.
    Hepatology. 2024;79:1365-1380.
    >> Share

  365. UMBAUGH DS, Nguyen NT, Curry SC, Rule JA, et al
    The chemokine CXCL14 is a novel early prognostic biomarker for poor outcome in acetaminophen-induced acute liver failure.
    Hepatology. 2024;79:1352-1364.
    >> Share

  366. WANG A, Blackford AL, Behling C, Wilson LA, et al
    Development of Fibro-PeN, a clinical prediction model for moderate-to-severe fibrosis in children with nonalcoholic fatty liver disease.
    Hepatology. 2024;79:1381-1392.
    >> Share

  367. JIN Y, Shou Y, Lei Q, Du C, et al
    An entropy weight method to integrate big omics and mechanistically evaluate DILI.
    Hepatology. 2024;79:1264-1278.
    >> Share

  368. AFONSO MB, Marques V, van Mil SWC, Rodrigues CMP, et al
    Human liver organoids: From generation to applications.
    Hepatology. 2024;79:1432-1451.
    >> Share

    May 2024
  369. MANTOVANI S, Mondelli MU
    Platelets harness innate immunity to promote dissemination of hepatocellular carcinoma.
    Hepatology. 2024 May 29. doi: 10.1097/HEP.0000000000000946.
    >> Share

  370. GUO C, Liu Z, Zhang T
    Reply: Regarding the use of decision curve analysis in predicting long-term complications of liver cirrhosis.
    Hepatology. 2024 May 29. doi: 10.1097/HEP.0000000000000947.
    >> Share

  371. MUSSO G, Pinach S, Mariano F, Saba F, et al
    Effect of phospholipid curcumin Meriva(R) on liver histology and kidney disease in nonalcoholic steatohepatitis a randomized, double-blind, placebo-controlled trial.
    Hepatology. 2024 May 28. doi: 10.1097/HEP.0000000000000937.
    >> Share

  372. LI B, Yang Y, Shi J, Li Y, et al
    Letter to the Editor: Molecular classification based on multi-omics facilitates prognostic stratification and personalized treatment in hepatocellular carcinoma.
    Hepatology. 2024 May 28. doi: 10.1097/HEP.0000000000000944.
    >> Share

  373. MOORE MP, Wang X, Kennelly JP, Shi H, et al
    Low MBOAT7 expression, a genetic risk for MASH, promotes a pro-fibrotic pathway involving hepatocyte TAZ upregulation.
    Hepatology. 2024 May 22. doi: 10.1097/HEP.0000000000000933.
    >> Share

  374. KANWAL F, Neuschwander-Tetri BA, Loomba R, Rinella ME, et al
    Metabolic dysfunction-associated steatotic liver disease: Update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease.
    Hepatology. 2024;79:1212-1219.
    >> Share

  375. NABI O, Lapidus N, Boursier J, de Ledinghen V, et al
    Reply: Concerns regarding the use of Fatty Liver Index in studies of lean NAFLD.
    Hepatology. 2024;79:E130-E131.
    >> Share

  376. ZAHRAWI FM, Mehal WZ
    Letter to the Editor: Concerns regarding the use of fatty liver index in studies of lean NAFLD.
    Hepatology. 2024;79:E129.
    >> Share

  377. STOCKDALE AJ, Degasperi E
    HDV RNA and liver disease progression: What do we know?
    Hepatology. 2024;79:983-985.
    >> Share

  378. DESERT R, Foucher F, Guillout M, Nieto N, et al
    Reply: Intratumor fibrotic HCC, a subtype matching the Hoshida S1 subclass?
    Hepatology. 2024;79:E141-E143.
    >> Share

  379. WANG TC, Xiao YD, Zhou P
    Letter to the Editor: Intratumor fibrotic HCC, a subtype matching the Hoshida S1 subclass?
    Hepatology. 2024;79:E140.
    >> Share

  380. LIU H, Li H, Wang DX, Li T, et al
    Letter to the Editor: Diagnostic accuracy of AGILE 3+ score for advanced fibrosis in patients with NAFLD: A systematic review and meta-analysis.
    Hepatology. 2024;79:E144-E145.
    >> Share

  381. DALBENI A, Mantovani A, Lombardi R, Ravaioli F, et al
    Reply: Diagnostic accuracy of AGILE3+ score for advanced fibrosis in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    Hepatology. 2024;79:E146-E147.
    >> Share

  382. KIRK FT, Munk DE, Swenson ES, Quicquaro AM, et al
    Effects of trientine and penicillamine on intestinal copper uptake: A mechanistic 64 Cu PET/CT study in healthy humans.
    Hepatology. 2024;79:1065-1074.
    >> Share

  383. SQUIRES JE, Horslen SP
    Incorporation of genetic testing into the diagnostic algorithms of PALF: The time is now.
    Hepatology. 2024;79:970-972.
    >> Share

  384. DALBENI A, Lombardi R, Henrique M, Zoncape M, et al
    Diagnostic accuracy of AGILE 3+ score for advanced fibrosis in patients with NAFLD: A systematic review and meta-analysis.
    Hepatology. 2024;79:1107-1116.
    >> Share

  385. LENZ D, Schlieben LD, Shimura M, Bianzano A, et al
    Genetic landscape of pediatric acute liver failure of indeterminate origin.
    Hepatology. 2024;79:1075-1087.
    >> Share

  386. AJMERA V, Tesfai K, Sandoval E, Lopez S, et al
    Validation of AGA clinical care pathway and AASLD practice guidance for nonalcoholic fatty liver disease in a prospective cohort of patients with type 2 diabetes.
    Hepatology. 2024;79:1098-1106.
    >> Share

  387. TONIUTTO P, Shalaby S, Mameli L, Morisco F, et al
    Role of sex in liver tumor occurrence and clinical outcomes: A comprehensive review.
    Hepatology. 2024;79:1141-1157.
    >> Share

  388. SANTOS AA, Delgado TC, Marques V, Ramirez-Moncayo C, et al
    Spatial metabolomics and its application in the liver.
    Hepatology. 2024;79:1158-1179.
    >> Share


  389. Erratum: Overexpressed-eIF3I interacted and activated oncogenic Akt1 is a theranostic target in human hepatocellular carcinoma.
    Hepatology. 2024;79:E150-E151.
    >> Share

    April 2024
  390. KUMAR M, Venishetty S
    Reply: Tranexamic acid in upper gastrointestinal bleed in patients with cirrhosis - A randomized controlled trial.
    Hepatology. 2024 Apr 30. doi: 10.1097/HEP.0000000000000916.
    >> Share

  391. ELKRIEF L, Denecheau-Girard C, Magaz M, Praktiknjo M, et al
    Abdominal surgery in patients with chronic noncirrhotic extra hepatic portal vein obstruction: A multicenter retrospective study.
    Hepatology. 2024 Apr 29. doi: 10.1097/HEP.0000000000000901.
    >> Share

  392. LI X, Zhang Y, Li S, Shi J, et al
    Macrophage hitchhiking for systematic suppression in postablative multifocal hepatocellular carcinoma.
    Hepatology. 2024 Apr 29. doi: 10.1097/HEP.0000000000000903.
    >> Share

  393. CHOPRA SY, Rawat VL, Ingle MA, Lad SG, et al
    Letter to Editor: Tranexamic acid in upper gastrointestinal bleed in patients with cirrhosis - a randomized controlled trial.
    Hepatology. 2024 Apr 29. doi: 10.1097/HEP.0000000000000915.
    >> Share

  394. OCHOA-ALLEMANT P, Serper M, Wang RX, Tang H, et al
    Waitlisting and liver transplantation for MetALD in the United States: An analysis of the UNOS national registry.
    Hepatology. 2024 Apr 29. doi: 10.1097/HEP.0000000000000914.
    >> Share

  395. HITOMI Y, Ueno K, Aiba Y, Nishida N, et al
    A genome-wide association study identified PTPN2 as a population-specific susceptibility gene locus for primary biliary cholangitis.
    Hepatology. 2024 Apr 23. doi: 10.1097/HEP.0000000000000894.
    >> Share

  396. LEE YT, Tseng HR, Yang JD
    Clonal hematopoiesis of indeterminate potential and risk of hepatocellular carcinoma: New kids on the block.
    Hepatology. 2024 Apr 19. doi: 10.1097/HEP.0000000000000898.
    >> Share

  397. GUO C, Liu Z, Fan H, Wang H, et al
    Machine learning-based plasma metabolomic profiles for predicting long-term complications of cirrhosis.
    Hepatology. 2024 Apr 17. doi: 10.1097/HEP.0000000000000879.
    >> Share

  398. HAZARI Y, Chevet E, Bailly-Maitre B, Hetz C, et al
    ER stress signaling at the interphase between MASH and hepatocellular carcinoma.
    Hepatology. 2024 Apr 16. doi: 10.1097/HEP.0000000000000893.
    >> Share

  399. PRZYBYSZEWSKI EM, Bhan I, Yarze JC
    Letter to the Editor: On the use of non-selective beta blockers in cirrhosis.
    Hepatology. 2024 Apr 16. doi: 10.1097/HEP.0000000000000888.
    >> Share

  400. GARCIA-TSAO G, Kaplan DE
    Reply: On the use of non-selective beta blockers in cirrhosis.
    Hepatology. 2024 Apr 16. doi: 10.1097/HEP.0000000000000889.
    >> Share

  401. VOLK ML
    Innovations in Healthcare Delivery for Patients with Cirrhosis.
    Hepatology. 2024 Apr 16. doi: 10.1097/HEP.0000000000000892.
    >> Share

  402. MOGHE A, McGuire BM, Levy C
    Acute hepatic porphyrias - a guide for Hepatologists.
    Hepatology. 2024 Apr 12. doi: 10.1097/HEP.0000000000000880.
    >> Share

  403. SUN C, Zhou C, Daneshvar K, Ben Saad A, et al
    Conserved long noncoding RNA TILAM promotes liver fibrosis through interaction with PML in hepatic stellate cells.
    Hepatology. 2024 Apr 2. doi: 10.1097/HEP.0000000000000822.
    >> Share

  404. LI J, Allen AM, Yin M
    Reply: Comparing quantitative MRI technologies in steatotic liver disease.
    Hepatology. 2024;79:E121-E122.
    >> Share

  405. ALKHOURI N, Harisinghani M
    Letter to the Editor: Comparing quantitative MRI technologies in steatotic liver disease.
    Hepatology. 2024;79:E119-E120.
    >> Share

  406. FRANSES JW, Duda DG
    Scirrhous HCC: Another 'omic thread in the HCC tapestry.
    Hepatology. 2024;79:747-748.
    >> Share

  407. VOLKERT I, Fromme M, Schneider C, Candels L, et al
    Impact of PNPLA3 I148M on alpha-1 antitrypsin deficiency-dependent liver disease progression.
    Hepatology. 2024;79:898-911.
    >> Share

  408. LADD AD, Duarte S, Sahin I, Zarrinpar A, et al
    Mechanisms of drug resistance in HCC.
    Hepatology. 2024;79:926-940.
    >> Share


  409. Erratum: Identification and characterization of a hepatic IL-13-producing ILC3-like population potentially involved in liver fibrosis.
    Hepatology. 2024;79:E128.
    >> Share


  410. Erratum: HCC EV ECG score: An extracellular vesicle-based protein assay for detection of early-stage hepatocellular carcinoma.
    Hepatology. 2024;79:E127.
    >> Share


  411. April 2024 Hepatology Highlights.
    Hepatology. 2024;79:745-746.
    >> Share

  412. TAFALENG EN, Li J, Wang Y, Hidvegi T, et al
    Variants in autophagy genes MTMR12 and FAM134A are putative modifiers of the hepatic phenotype in alpha1-antitrypsin deficiency.
    Hepatology. 2024 Apr 1. doi: 10.1097/HEP.0000000000000865.
    >> Share

  413. TAPPER EB, Warner MA, Shah RP, Emamaullee J, et al
    Management of coagulopathy among patients with cirrhosis undergoing upper endoscopy and paracentesis: Persistent gaps and areas of consensus in a multispecialty Delphi.
    Hepatology. 2024 Apr 1. doi: 10.1097/HEP.0000000000000856.
    >> Share

    March 2024

  414. Erratum: AASLD Practice Guidance on Acute-on-chronic liver failure and the management of critically ill patients with cirrhosis.
    Hepatology. 2024 Mar 29. doi: 10.1097/HEP.0000000000000857.
    >> Share

  415. DENG T, Chen G
    Single-cell based molecular classification in systematic treatment of hepatocellular carcinoma: From in silico to bedside.
    Hepatology. 2024 Mar 28. doi: 10.1097/HEP.0000000000000874.
    >> Share

  416. CRUZ C, Prado CM, Gillis C, Martindale R, et al
    Nutritional aspects of prehabilitation in adults with cirrhosis awaiting liver transplant.
    Hepatology. 2024 Mar 28. doi: 10.1097/HEP.0000000000000818.
    >> Share

  417. FENG X, Feng B, Zhou J, Yang J, et al
    Mesenchymal stem cells alleviate mouse liver fibrosis by inhibiting pathogenic function of intrahepatic B cells.
    Hepatology. 2024 Mar 28. doi: 10.1097/HEP.0000000000000831.
    >> Share

  418. GOLDBERG DT, Yaskolka Meir A, Tsaban G, Rinott E, et al
    Novel proteomic signatures may indicate MRI-assessed intrahepatic fat state and changes; the DIRECT PLUS clinical trial.
    Hepatology. 2024 Mar 27. doi: 10.1097/HEP.0000000000000867.
    >> Share

  419. ZHAO Q, Chen DP, Chen HD, Wang YZ, et al
    NK-cell-elicited gasdermin-D-dependent hepatocyte pyroptosis induces neutrophil extracellular traps that facilitates HBV-related acute-on-chronic liver failure.
    Hepatology. 2024 Mar 27. doi: 10.1097/HEP.0000000000000868.
    >> Share

  420. CHEN Y, Deng X, Li Y, Han Y, et al
    Comprehensive molecular classification predicted microenvironment profiles and therapy response for hepatocellular carcinoma.
    Hepatology. 2024 Mar 27. doi: 10.1097/HEP.0000000000000869.
    >> Share

  421. CULLARO G, Allegretti AS, Fenton C, Ge J, et al
    The association between mean arterial pressure and acute kidney injury reversal among decompensated cirrhosis patients.
    Hepatology. 2024 Mar 27. doi: 10.1097/HEP.0000000000000858.
    >> Share

  422. WIGG AJ, Narayana S, Woodman RJ, Adams LA, et al
    A randomized multicenter trial of a chronic disease management intervention for decompensated cirrhosis. The Australian Liver Failure (ALFIE) trial.
    Hepatology. 2024 Mar 27. doi: 10.1097/HEP.0000000000000862.
    >> Share

  423. MEROUEH C, Warasnhe K, Tizhoosh HR, Shah VH, et al
    Digital pathology and spatial omics in steatohepatitis: Clinical applications and discovery potentials.
    Hepatology. 2024 Mar 22. doi: 10.1097/HEP.0000000000000866.
    >> Share

  424. JONES DE, Beuers U, Bonder A, Carbone M, et al
    Primary biliary cholangitis drug evaluation and regulatory approval: Where do we go from here?
    Hepatology. 2024 Mar 22. doi: 10.1097/HEP.0000000000000864.
    >> Share

  425. STERLING RK, Asrani SK, Levine D, Duarte-Rojo A, et al
    AASLD Practice Guideline on non-invasive liver disease assessments of portal hypertension.
    Hepatology. 2024 Mar 15. doi: 10.1097/HEP.0000000000000844.
    >> Share

  426. STERLING RK, Patel K, Duarte-Rojo A, Asrani SK, et al
    AASLD Practice Guideline on blood-based non-invasive liver disease assessments of hepatic fibrosis and steatosis.
    Hepatology. 2024 Mar 15. doi: 10.1097/HEP.0000000000000845.
    >> Share

  427. STERLING RK, Duarte-Rojo A, Patel K, Asrani SK, et al
    AASLD Practice Guideline on imaging-based non-invasive liver disease assessments of hepatic fibrosis and steatosis.
    Hepatology. 2024 Mar 15. doi: 10.1097/HEP.0000000000000843.
    >> Share

  428. ROCKEY DC, Alsawas M, Rojo-Duarte A, Patel K, et al
    Non-invasive liver disease assessment to identify portal hypertension: A systematic review supporting the AASLD Practice Guideline.
    Hepatology. 2024 Mar 15. doi: 10.1097/HEP.0000000000000841.
    >> Share

  429. DIETZ-FRICKE C, Degasperi E, Jachs M, Maasoumy B, et al
    Safety and efficacy of off-label bulevirtide monotherapy in HDV patients with decompensated Child-B cirrhosis - a real world case series.
    Hepatology. 2024 Mar 13. doi: 10.1097/HEP.0000000000000847.
    >> Share

  430. MARCHETTI A, Pelusi S, Marella A, Malvestiti F, et al
    Impact of clonal hematopoiesis of indeterminate potential on hepatocellular carcinoma in individuals with steatotic liver disease.
    Hepatology. 2024 Mar 11. doi: 10.1097/HEP.0000000000000839.
    >> Share

  431. BU W, Sun X, Xue X, Geng S, et al
    Early onset of pathological polyploidization and cellular senescence in hepatocytes lacking RAD51 creates a pro-fibrotic and pro-tumorigenic inflammatory microenvironment.
    Hepatology. 2024 Mar 11. doi: 10.1097/HEP.0000000000000821.
    >> Share

  432. MUNOZ AE, Rodger EG
    Letter to the Editor: Emerging role of statin therapy in the prevention and management of cirrhosis, portal hypertension, and HCC.
    Hepatology. 2024 Mar 11. doi: 10.1097/HEP.0000000000000846.
    >> Share

  433. SHARPTON S, Loomba R
    Response to Letter to the Editor: emerging role of statin therapy in the prevention and management of cirrhosis, portal hypertension, and HCC.
    Hepatology. 2024 Mar 11. doi: 10.1097/HEP.0000000000000848.
    >> Share

  434. GUO Q, Wang J, Wang G, Wang X, et al
    Letter to the Editor: Is right heart assessment vital for evaluating Terlipressin-related outcomes in Hepatorenal Syndrome-AKI?
    Hepatology. 2024 Mar 8. doi: 10.1097/HEP.0000000000000832.
    >> Share

  435. CHAPMAN B, Wong D, Sinclair M, Hey P, et al
    Reversing malnutrition and low muscle strength with targeted enteral feeding in patients awaiting liver transplant: A randomized controlled trial.
    Hepatology. 2024 Mar 8. doi: 10.1097/HEP.0000000000000840.
    >> Share

  436. BERENGUER J, Aldamiz-Echevarria T, Hontanon V, Fanciulli C, et al
    Clinical outcomes and prognostic factors after HCV clearance with DAA in HIV/HCV coinfected patients with advanced Fibrosis/Cirrhosis.
    Hepatology. 2024 Mar 7. doi: 10.1097/HEP.0000000000000838.
    >> Share

  437. SEMMLER G, Hartl L, Mendoza YP, Simbrunner B, et al
    Simple blood tests to diagnose compensated advanced chronic liver disease and stratify risk of clinically significant portal hypertension.
    Hepatology. 2024 Mar 6. doi: 10.1097/HEP.0000000000000829.
    >> Share

  438. AMPUERO J, Lucena A, Berenguer M, Hernandez-Guerra M, et al
    Predictive factors for decompensating events in cirrhotic patients with primary biliary cholangitis under different lines of therapy.
    Hepatology. 2024 Mar 6. doi: 10.1097/HEP.0000000000000826.
    >> Share

  439. LAL BB, Alam S, Sibal A, Kumar K, et al
    Genotype correlates with clinical course and outcome of children with tight junction protein 2 (TJP2) deficiency-related cholestasis.
    Hepatology. 2024 Mar 6. doi: 10.1097/HEP.0000000000000828.
    >> Share

  440. ROY A, Kajal K, Izzy M, Sihag BK, et al
    Reply: Is right heart assessment vital for evaluating terlipressin-related outcomes in Hepatorenal Syndrome-AKI ?
    Hepatology. 2024 Mar 5. doi: 10.1097/HEP.0000000000000833.
    >> Share

  441. KUMAR M, Venishetty S, Jindal A, Bihari C, et al
    Tranexamic acid in upper gastrointestinal bleed in patients with cirrhosis - a randomized controlled trial.
    Hepatology. 2024 Mar 5. doi: 10.1097/HEP.0000000000000817.
    >> Share


  442. Erratum: An integrated analysis of fecal microbiome and metabolomic features distinguish non-cirrhotic NASH from healthy control populations.
    Hepatology. 2024;79:E105.
    >> Share

  443. HOOFNAGLE JH, Doo E
    Letter to the Editor: A multi-society Delphi consensus statement on new fatty liver disease nomenclature.
    Hepatology. 2024;79:E91-E92.
    >> Share

  444. LAZARUS JV, Newsome PN, Francque SM, Kanwal F, et al
    Reply: A multi-society Delphi consensus statement on new fatty liver disease nomenclature.
    Hepatology. 2024;79:E93-E94.
    >> Share

  445. BARMAN-AKSOZEN J, Minder AE, Schuppan D, Stolzel U, et al
    Letter to the Editor: Contrasting effect of iron supplementation in protoporphyria.
    Hepatology. 2024;79:E87-E88.
    >> Share

  446. LEVY C, Dickey AK, Anderson KE, Keel SB, et al
    Reply: Contrasting effect of iron supplementation in protoporphyria.
    Hepatology. 2024;79:E89-E90.
    >> Share

  447. NICOARA-FARCAU O, Han G, Rudler M, Angrisani D, et al
    Pre-emptive TIPS in high-risk acute variceal bleeding. An updated and revised individual patient data meta-analysis.
    Hepatology. 2024;79:624-635.
    >> Share

  448. WANG F, Chen L, Kong D, Zhang X, et al
    Canonical Wnt signaling promotes HSC glycolysis and liver fibrosis through an LDH-A/HIF-1alpha transcriptional complex.
    Hepatology. 2024;79:606-623.
    >> Share

  449. LEE BP, Dodge JL, Terrault NA
    National prevalence estimates for steatotic liver disease and subclassifications using consensus nomenclature.
    Hepatology. 2024;79:666-673.
    >> Share

  450. BARTEN TRM, Atsma F, van der Meer AJ, Gansevoort R, et al
    Higher need for polycystic liver disease therapy in female patients: Sex-specific association between liver volume and need for therapy.
    Hepatology. 2024;79:551-559.
    >> Share

  451. LEDENKO M, Antwi SO, Patel T
    Geospatial analysis of cyanobacterial exposure and liver cancer in the contiguous United States.
    Hepatology. 2024;79:575-588.
    >> Share

  452. LEVY C, Dickey AK, Wang B, Thapar M, et al
    Evidence-based consensus guidelines for the diagnosis and management of protoporphyria-related liver dysfunction in erythropoietic protoporphyria and X-linked protoporphyria.
    Hepatology. 2024;79:731-743.
    >> Share


  453. Hepatology Highlights.
    Hepatology. 2024;79:525-526.
    >> Share

    February 2024
  454. WONG YJ, Teng M, Sim A, Thet HM, et al
    Full adherence to cirrhosis quality indicators is associated with lower mortality in acute variceal bleeding: Nationwide audit.
    Hepatology. 2024 Feb 20. doi: 10.1097/HEP.0000000000000793.
    >> Share

  455. HASSAN MM, Li D, Han Y, Byun J, et al
    Genome-wide association study identifies high-impact susceptibility loci for hepatocellular carcinoma in North America.
    Hepatology. 2024 Feb 20. doi: 10.1097/HEP.0000000000000800.
    >> Share

  456. ENGELSKIRCHER SA, Chen PC, Strunz B, Oltmanns C, et al
    Impending hepatocellular carcinoma diagnosis in cirrhotic patients after HCV cure features a natural killer cell signature.
    Hepatology. 2024 Feb 20. doi: 10.1097/HEP.0000000000000804.
    >> Share

  457. PENG Z, Wei G, Huang P, Matta H, et al
    ASK1/p38 axis inhibition blocks the release of mitochondrial "danger signals" from hepatocytes and suppresses progression to cirrhosis and liver cancer.
    Hepatology. 2024 Feb 20. doi: 10.1097/HEP.0000000000000801.
    >> Share

  458. HE B, Huang Z, Qin S, Peng P, et al
    Enhanced SLC35B2/SAV1 sulfation axis promotes tumor growth through inhibiting Hippo signaling in hepatocellular carcinoma.
    Hepatology. 2024 Feb 20. doi: 10.1097/HEP.0000000000000783.
    >> Share

  459. CALTHORPE L, Chiou SH, Rubin J, Huang CY, et al
    A modified hospital frailty risk score for patients with cirrhosis undergoing abdominal operations.
    Hepatology. 2024 Feb 19. doi: 10.1097/HEP.0000000000000794.
    >> Share

  460. PREMKUMAR M, Kajal K, Izzy M, Sihag BK, et al
    Reply to 'liver, heart, and kidney crosstalk in cirrhosis: POCUS is the focus".
    Hepatology. 2024 Feb 16. doi: 10.1097/HEP.0000000000000792.
    >> Share

  461. PAPATHERODORIDIS G, Lampertico P
    Hepatocellular carcinoma risk in HBeAg-positive chronic hepatitis B patients under long-term nucleos(t)ide analogue therapy: New insights from Asia.
    Hepatology. 2024 Feb 16. doi: 10.1097/HEP.0000000000000796.
    >> Share

  462. ZHU M, Liu Z, Chen S, Luo Z, et al
    Sintilimab plus bevacizumab combined with radiotherapy as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A multicenter, single-arm, phase 2 study.
    Hepatology. 2024 Feb 15. doi: 10.1097/HEP.0000000000000776.
    >> Share

  463. PARK JG, Roh PR, Kang MW, Cho SW, et al
    Intrahepatic immunoglobulin a complex induces polarization of cancer-associated fibroblasts to matrix phenotypes in the tumor microenvironment of hepatocellular carcinoma.
    Hepatology. 2024 Feb 15. doi: 10.1097/HEP.0000000000000772.
    >> Share

  464. DONGELMANS E, Erler N, Adam R, Nadalin S, et al
    Recent outcomes of liver transplantation for Budd Chiari Syndrome - a study of the European Liver Transplant Registry (ELTR) and affiliated centers.
    Hepatology. 2024 Feb 15. doi: 10.1097/HEP.0000000000000778.
    >> Share

  465. AGRAWAL D, Ariga KK
    Liver, heart, and kidney crosstalk in cirrhosis: POCUS is the focus.
    Hepatology. 2024 Feb 14. doi: 10.1097/HEP.0000000000000789.
    >> Share

  466. ALLEGRETTI AS, Patidar KR, Ma AT, Cullaro G, et al
    From past to present to future: Terlipressin and hepatorenal syndrome-acute kidney injury.
    Hepatology. 2024 Feb 14. doi: 10.1097/HEP.0000000000000790.
    >> Share

  467. MOCTEZUMA-VELAZQUEZ C, Wong YJ, Montano-Loza AJ
    Editorial: Promise and pitfalls of a natural killer cell signature for hepatocellular carcinoma detection in HCV patients with sustained virological response.
    Hepatology. 2024 Feb 14. doi: 10.1097/HEP.0000000000000797.
    >> Share

  468. EHRENBAUER AF, Egge JFM, Gabriel MM, Tiede A, et al
    Comparison of six tests for diagnosing minimal hepatic encephalopathy and predicting clinical outcome - A prospective, observational study.
    Hepatology. 2024 Feb 13. doi: 10.1097/HEP.0000000000000770.
    >> Share

  469. RINELLA ME, Castro Narro GE, Krag A, Terrault N, et al
    Reply: 'From NAFLD to MASLD: Promise and pitfalls of a new definition' dagger.
    Hepatology. 2024;79:E16-E17.
    >> Share

  470. CUSI K, Younossi Z, Roden M
    From NAFLD to MASLD: Promise and pitfalls of a new definition dagger.
    Hepatology. 2024;79:E13-E15.
    >> Share

  471. BALAKRISHNAN M, Rehm J
    A public health perspective on mitigating the global burden of chronic liver disease.
    Hepatology. 2024;79:451-459.
    >> Share

  472. KHALID M, Khan ZM, Sheraz Kahloon A
    Letter to the Editor: NAFLD improves risk prediction of type 2 diabetes-With effect modification by sex and menopausal status.
    Hepatology. 2024;79:E18-E19.
    >> Share

  473. KIM Y, Chang Y, Ryu S, Wild SH, et al
    Reply: NAFLD improves risk prediction of type 2 diabetes-With effect modification by sex and menopausal status.
    Hepatology. 2024;79:E20-E21.
    >> Share

  474. BARR RG, Bolondi L
    Contrast-enhanced US for HCC: Finally out from the waiting list?
    Hepatology. 2024;79:267-268.
    >> Share

  475. LYSHCHIK A, Wessner CE, Bradigan K, Eisenbrey JR, et al
    Contrast-enhanced ultrasound liver imaging reporting and data system: clinical validation in a prospective multinational study in North America and Europe.
    Hepatology. 2024;79:380-391.
    >> Share

  476. HUANG H, Tsui YM, Ho DW, Chung CY, et al
    LANCL1, a cell surface protein, promotes liver tumor initiation through FAM49B-Rac1 axis to suppress oxidative stress.
    Hepatology. 2024;79:323-340.
    >> Share

  477. LAZARUS JV, Mark HE, Allen AM, Arab JP, et al
    A global action agenda for turning the tide on fatty liver disease.
    Hepatology. 2024;79:502-523.
    >> Share

  478. MENG Z, Zhou L, Hong S, Qiu X, et al
    Myeloid-specific ablation of Basp1 ameliorates diet-induced NASH in mice by attenuating pro-inflammatory signaling.
    Hepatology. 2024;79:409-424.
    >> Share

  479. SINHA S, Hassan N, Schwartz RE
    Organelle stress and alterations in interorganelle crosstalk during liver fibrosis.
    Hepatology. 2024;79:482-501.
    >> Share


  480. Hepatology Highlights.
    Hepatology. 2024;79:255-256.
    >> Share


  481. Hepatology Highlights.
    Hepatology. 2024;79:255-256.
    >> Share

    January 2024

  482. Erratum: Inhibition of microRNA-24 expression in liver prevents hepatic lipid accumulation and hyperlipidemia.
    Hepatology. 2024 Jan 29. doi: 10.1097/HEP.0000000000000730.
    >> Share

  483. WANG Y, Wang X, Bai B, Shaha A, et al
    Targeting Src SH3 domain-mediated glycolysis of hepatic stellate cells suppresses transcriptome, myofibroblastic activation, and colorectal liver metastasis.
    Hepatology. 2024 Jan 24. doi: 10.1097/HEP.0000000000000763.
    >> Share

  484. XIA Y, Wang Y, Xiong Q, He J, et al
    Neutrophil extracellular traps promote MASH fibrosis by metabolic reprogramming of hepatic stellate cells.
    Hepatology. 2024 Jan 24. doi: 10.1097/HEP.0000000000000762.
    >> Share


  485. Hepatology highlights.
    Hepatology. 2024 Jan 23. doi: 10.1097/HEP.0000000000000742.
    >> Share

  486. NAKAGAWA H, Lin A
    The translation of oncogenic mRNAs regulated by pseudouridylation: A new player in hepatocellular carcinoma.
    Hepatology. 2024 Jan 22. doi: 10.1097/HEP.0000000000000761.
    >> Share

  487. NIEMIETZ P, Peiseler M, Kohlhepp M, Horn P, et al
    C-C chemokine receptor type 7 (CCR7) regulates hepatic CD8+ T cell homeostasis and response to acute liver injury.
    Hepatology. 2024 Jan 17. doi: 10.1097/HEP.0000000000000757.
    >> Share

  488. TRIPODI A, Primignani M, D'Ambrosio R, Tosetti G, et al
    Reappraisal of the conventional hemostasis tests as predictors of perioperative bleeding in the era of rebalanced hemostasis in cirrhosis.
    Hepatology. 2024 Jan 12. doi: 10.1097/HEP.0000000000000756.
    >> Share


  489. Hepatology Highlights.
    Hepatology. 2024;79:1-2.
    >> Share

  490. BARGELLINI I, Rimassa L, Masi G
    SIRT and chemotherapy in unresectable iCCA: Ready to take off.
    Hepatology. 2024;79:9-11.
    >> Share

  491. EMANUELE E, Minoretti P
    Letter to the Editor: NAFLD, MAFLD or MASLD? Cut the Gordian knot with "Ludwig disease".
    Hepatology. 2024;79:E4.
    >> Share

  492. NEWSOME P, Rinella ME, Lazarus JV, Terrault N, et al
    Reply: NAFLD, MAFLD, or MASLD? Cut the Gordian knot with "Ludwig disease".
    Hepatology. 2024;79:E5-E6.
    >> Share

  493. ROWE IA
    Prediction of outcomes in patients with acute variceal bleeding.
    Hepatology. 2024;79:15-17.
    >> Share

  494. WANG CC, Cheng YM, Kao JH
    Letter to the Editor: Statement of steatotic liver disease-A great leap toward the global standardization.
    Hepatology. 2024;79:E7-E8.
    >> Share

  495. GARCIA-CRIADO A, Bruix J
    Screening for liver cancer: The good, the bad, and the ugly.
    Hepatology. 2024;79:12-14.
    >> Share

  496. CORPECHOT C, Lemoinne S, Soret PA, Hansen B, et al
    Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain?
    Hepatology. 2024;79:39-48.
    >> Share

  497. LEE EW, Eghtesad B, Garcia-Tsao G, Haskal ZJ, et al
    AASLD Practice Guidance on the use of TIPS, variceal embolization, and retrograde transvenous obliteration in the management of variceal hemorrhage.
    Hepatology. 2024;79:224-250.
    >> Share


  498. Hepatology Highlights.
    Hepatology. 2024;79:1-2.
    >> Share

    December 2023
  499. HOFER BS, Brusilovskaya K, Simbrunner B, Balcar L, et al
    Decreased platelet activation predicts hepatic decompensation and mortality in patients with cirrhosis.
    Hepatology. 2023 Dec 27. doi: 10.1097/HEP.0000000000000740.
    >> Share

  500. VAJRO P, Mandato C
    Letter to the Editor: More on Non-Alcohol/Non-Metabolic Dysfunction-Associated Steatohepatitis.
    Hepatology. 2023 Dec 27. doi: 10.1097/HEP.0000000000000734.
    >> Share

  501. JENG WJ, Chien RN, Liaw YF
    Reply: Halting antiviral therapy in patients with cirrhosis and chronic hepatitis B: A dangerous game?
    Hepatology. 2023 Dec 27. doi: 10.1097/HEP.0000000000000737.
    >> Share

  502. CORPECHOT C, Lemoinne S, Soret PA, Chazouilleres O, et al
    Reply: Improving access to transient elastography data for Real-World Prognostic Applications in primary biliary cholangitis.
    Hepatology. 2023 Dec 27. doi: 10.1097/HEP.0000000000000746.
    >> Share

  503. WIEGAND J, Franke A, Stein K, Trautwein C, et al
    Letter to the Editor: Improving access to transient elastography data for real-world prognostic applications in primary biliary cholangitis.
    Hepatology. 2023 Dec 27. doi: 10.1097/HEP.0000000000000744.
    >> Share

  504. WATT KD, Khan MQ
    Reply to "more on non-alcohol/non-metabolic dysfunction-associated steatohepatitis".
    Hepatology. 2023 Dec 26. doi: 10.1097/HEP.0000000000000739.
    >> Share

  505. CHEN J, Tu T, Cohen C, Wang S, et al
    Letter to the Editor: Halting antiviral therapy in patients with cirrhosis and chronic hepatitis B: A dangerous game?
    Hepatology. 2023 Dec 26. doi: 10.1097/HEP.0000000000000732.
    >> Share

  506. ZABRANSKY DJ, Yarchoan M, Ho WJ
    Reply: The Hepa 1-6 may not be suitable for use in hepatocellular carcinoma models to explore responses to drug therapy.
    Hepatology. 2023 Dec 26. doi: 10.1097/HEP.0000000000000738.
    >> Share

  507. LU T, Zhang J, Li H, Li G, et al
    Letter to the Editor: The Hepa 1-6 may not be suitable for use in hepatocellular carcinoma models to explore responses to drug therapy.
    Hepatology. 2023 Dec 25. doi: 10.1097/HEP.0000000000000733.
    >> Share

  508. KREMER AE, Mayo MJ, Hirschfield GM, Levy C, et al
    Seladelpar treatment reduces interleukin-31 and pruritus in patients with primary biliary cholangitis.
    Hepatology. 2023 Dec 20. doi: 10.1097/HEP.0000000000000728.
    >> Share

  509. RATZIU V, Francque S, Behling CA, Cejvanovic V, et al
    Artificial intelligence scoring of liver biopsies in a phase ii trial of semaglutide in non-alcoholic steatohepatitis.
    Hepatology. 2023 Dec 19. doi: 10.1097/HEP.0000000000000723.
    >> Share

  510. VOGEL A, Grant RC, Meyer T, Sapisochin G, et al
    Adjuvant and neoadjuvant therapies for hepatocellular carcinoma.
    Hepatology. 2023 Dec 18. doi: 10.1097/HEP.0000000000000726.
    >> Share

  511. SIDDIQUI MS, Muthiah M, Satapathy SK, Patidar K, et al
    Defining an approach for therapeutic strategies in metabolic dysfunction-associated steatotic liver disease after liver transplantation.
    Hepatology. 2023 Dec 13. doi: 10.1097/HEP.0000000000000720.
    >> Share

  512. SCHULZE RJ, Strom SC, Nyberg SL
    From pain to gain: Leveraging acetaminophen in hepatocyte transplantation for phenylketonuria.
    Hepatology. 2023 Dec 12. doi: 10.1097/HEP.0000000000000713.
    >> Share

  513. YU S, Liu X, Xu Y, Pan L, et al
    m6A-mediated gluconeogenic enzyme PCK1 upregulation protects against hepatic ischemia-reperfusion injury.
    Hepatology. 2023 Dec 12. doi: 10.1097/HEP.0000000000000716.
    >> Share

  514. YIN C, Zhang C, Wang Y, Liu G, et al
    ALDOB/KAT2A interactions epigenetically modulate TGF-beta expression and T cell functions in hepatocellular carcinogenesis.
    Hepatology. 2023 Dec 5. doi: 10.1097/HEP.0000000000000704.
    >> Share

  515. CHAN FF, Yuen VW, Shen J, Chin DW, et al
    Inhibition of CAF-1 histone chaperone complex triggers cytosolic DNA and dsRNA sensing pathways and induces intrinsic immunity of hepatocellular carcinoma.
    Hepatology. 2023 Dec 5. doi: 10.1097/HEP.0000000000000709.
    >> Share

  516. MALHI H, Brown RS Jr, Lim JK, Reau N, et al
    Precipitous changes in nomenclature and definitions-NAFLD becomes SLD: Implications for and expectations of AASLD journals.
    Hepatology. 2023;78:1680-1681.
    >> Share

  517. RINELLA ME, Lazarus JV, Ratziu V, Francque SM, et al
    A multisociety Delphi consensus statement on new fatty liver disease nomenclature.
    Hepatology. 2023;78:1966-1986.
    >> Share

  518. DESAI AP, Madathanapalli A, Tang Q, Orman ES, et al
    PROMIS Profile-29 is a valid instrument with distinct advantages over legacy instruments for measuring the quality of life in chronic liver disease.
    Hepatology. 2023;78:1788-1799.
    >> Share

  519. ABERG F
    Letter to the Editor: ELF in the risk stratification of NAFLD-Are the ELF thresholds suggested by the AASLD guidelines appropriate?
    Hepatology. 2023;78:E101-E102.
    >> Share

  520. RINELLA ME, Terrault N, Neuschwander-Tetri B, Loomba R, et al
    Reply: ELF in the risk stratification of NAFLD-Are the ELF thresholds suggested by the AASLD guidelines appropriate?
    Hepatology. 2023;78:E103-E104.
    >> Share

  521. ZHANG X, Yip TC, Tse YK, Hui VW, et al
    Duration of type 2 diabetes and liver-related events in nonalcoholic fatty liver disease: A landmark analysis.
    Hepatology. 2023;78:1816-1827.
    >> Share

  522. GAO R, Li Y, Xu Z, Zhang F, et al
    Mitochondrial pyruvate carrier 1 regulates fatty acid synthase lactylation and mediates treatment of nonalcoholic fatty liver disease.
    Hepatology. 2023;78:1800-1815.
    >> Share


  523. Erratum: Interleukin-18 signaling promotes activation of hepatic stellate cells in mouse liver fibrosis.
    Hepatology. 2023;78:E110.
    >> Share


  524. Erratum: Diabetes and cirrhosis: Current concepts on diagnosis and management.
    Hepatology. 2023;78:E108.
    >> Share


  525. Erratum: Inhibition of mPGES-2 ameliorates non-alcoholic steatohepatitis by activating NR1D1 via heme.
    Hepatology. 2023;78:E107.
    >> Share

  526. MAIWALL R, Piano S, Singh V, Caraceni P, et al
    Determinants of clinical response to empirical antibiotic treatment in patients with cirrhosis and bacterial and fungal infections- Results from the ICA 'Global study' [EABCIR-Global Study].
    Hepatology. 2023 Dec 1. doi: 10.1097/HEP.0000000000000653.
    >> Share


  527. Ending stigmatizing language in alcohol and liver disease: A liver societies' statement dagger.
    Hepatology. 2023;78:1682-1683.
    >> Share

    November 2023
  528. HU YX, Diao LT, Hou YR, Lv G, et al
    PUS1 promotes hepatocellular carcinoma via mRNA pseudouridylation to enhance the translation of oncogenic mRNAs.
    Hepatology. 2023 Nov 28. doi: 10.1097/HEP.0000000000000702.
    >> Share

  529. PREMKUMAR M, Kajal K, Reddy KR, Izzy M, et al
    Evaluation of terlipressin-related patient outcomes in hepatorenal syndrome-acute kidney injury using point-of-care echocardiography.
    Hepatology. 2023 Nov 17. doi: 10.1097/HEP.0000000000000691.
    >> Share

  530. MICHALOPOULOS GK
    Hepatocytes of mice and men: Different regenerative signals?
    Hepatology. 2023 Nov 16. doi: 10.1097/HEP.0000000000000693.
    >> Share

  531. KE L, Rui Z, Fukai W, Yunzheng Z, et al
    Single-cell dissection of the multicellular ecosystem and molecular features underlying microvascular invasion in hepatocellular carcinoma.
    Hepatology. 2023 Nov 16. doi: 10.1097/HEP.0000000000000673.
    >> Share


  532. February 2024 Hepatology Highlights.
    Hepatology. 2023 Nov 16. doi: 10.1097/HEP.0000000000000681.
    >> Share

  533. VAN DER MEEREN PE, Frederik de Wilde R, Sprengers D, IJzermans JNM, et al
    Benefit and harm of waiting time in liver transplantation for HCC.
    Hepatology. 2023 Nov 16. doi: 10.1097/HEP.0000000000000668.
    >> Share

  534. LIU N, Tian J, Steer CJ, Han Q, et al
    MicroRNA-206-3p suppresses hepatic lipogenesis and cholesterol synthesis while driving cholesterol efflux.
    Hepatology. 2023 Nov 9. doi: 10.1097/HEP.0000000000000672.
    >> Share

  535. KARVELLAS CJ, Bajaj JS, Kamath PS, Napolitano L, et al
    AASLD Practice guidance on Acute-on-chronic liver failure and the management of critically Ill patients with cirrhosis.
    Hepatology. 2023 Nov 9. doi: 10.1097/HEP.0000000000000671.
    >> Share

  536. QASIM KHAN M, Hassan S, Lizaola-Mayo BC, Bhat M, et al
    Navigating the 'Specific Etiology' steatohepatitis category: Evaluation & management of non-alcohol/non-metabolic dysfunction-associated steatohepatitis.
    Hepatology. 2023 Nov 7. doi: 10.1097/HEP.0000000000000674.
    >> Share

  537. BRENNER DA
    Alternatives to animal testing to assess NASH drugs and hepatotoxicity.
    Hepatology. 2023 Nov 6. doi: 10.1097/HEP.0000000000000669.
    >> Share

  538. SCHERR AL, Nader L, Xu K, Elssner C, et al
    Etiology-independent activation of the LTbeta-LTbetaR-RELB axis drives aggressiveness and predicts poor prognosis in Hepatocellular carcinoma.
    Hepatology. 2023 Nov 2. doi: 10.1097/HEP.0000000000000657.
    >> Share

  539. D'AMICO G, Zipprich A, Villanueva C, Sorda JA, et al
    Further decompensation in cirrhosis. Results of a large multicenter cohort study supporting Baveno VII statements.
    Hepatology. 2023 Nov 2. doi: 10.1097/HEP.0000000000000652.
    >> Share

  540. RINELLA ME, Terrault N, Neuschwander-Tetri B, Loomba R, et al
    Reply: People living with HIV and NAFLD and updated guidance on NAFLD screening.
    Hepatology. 2023;78:E91-E92.
    >> Share

  541. ARIAS-LOSTE MT, Crespo J, Iruzubieta P
    Letter to the Editor: Updated guidance on NAFLD screening.
    Hepatology. 2023;78:E89-E90.
    >> Share

  542. SEBASTIANI G, Milic J, Tsochatzis EA, Marzolini C, et al
    Letter to the Editor: People living with HIV and NAFLD-A population left behind in the global effort for liver fibrosis screening?
    Hepatology. 2023;78:E87-E88.
    >> Share

  543. YANG Z, Ding WX
    The pre-mRNA alternative splicing regulated by SRPK2: A new player in alcohol-associated liver disease?
    Hepatology. 2023;78:1329-1331.
    >> Share

  544. LAZARUS JV, Kopka CJ, Younossi ZM, Allen AM, et al
    It is time to expand the fatty liver disease community of practice.
    Hepatology. 2023;78:1325-1328.
    >> Share

  545. TILG H, Adolph TE, Tacke F
    Therapeutic modulation of the liver immune microenvironment.
    Hepatology. 2023;78:1581-1601.
    >> Share

  546. NIKNEJAD N, Fox D, Burwinkel JL, Zarrin-Khameh N, et al
    ASO silencing of a glycosyltransferase, Poglut1 , improves the liver phenotypes in mouse models of Alagille syndrome.
    Hepatology. 2023;78:1337-1351.
    >> Share

  547. WU Q, Pan C, Zhou Y, Wang S, et al
    Targeting neuropilin-1 abolishes anti-PD-1-upregulated regulatory T cells and synergizes with 4-1BB agonist for liver cancer treatment.
    Hepatology. 2023;78:1402-1417.
    >> Share

  548. SONG Y, Wei J, Li R, Fu R, et al
    Tyrosine kinase receptor B attenuates liver fibrosis by inhibiting TGF-beta/SMAD signaling.
    Hepatology. 2023;78:1433-1447.
    >> Share

  549. CHIU YT, Husain A, Sze KM, Ho DW, et al
    Midline 1 interacting protein 1 promotes cancer metastasis through FOS-like 1-mediated matrix metalloproteinase 9 signaling in HCC.
    Hepatology. 2023;78:1368-1383.
    >> Share

  550. YANG F, Hilakivi-Clarke L, Shaha A, Wang Y, et al
    Metabolic reprogramming and its clinical implication for liver cancer.
    Hepatology. 2023;78:1602-1624.
    >> Share

  551. LEE CM, Yoon EL, Kim M, Kang BK, et al
    Prevalence, distribution and hepatic fibrosis burden of the different subtypes of steatotic liver disease in primary care settings.
    Hepatology. 2023 Nov 1. doi: 10.1097/HEP.0000000000000664.
    >> Share

  552. BRAILLON A, Naudet F
    Letter to the Editor: Medications promoting abstinence in alcohol-associated cirrhosis.
    Hepatology. 2023 Nov 1. doi: 10.1097/HEP.0000000000000656.
    >> Share

    October 2023
  553. JENG WJ, Chien RN, Liaw YF
    Reply: Cautious interpretation of the association between finite treatment and better prognosis in initially HBeAg-negative hepatitis B patients with cirrhosis.
    Hepatology. 2023 Oct 31. doi: 10.1097/HEP.0000000000000662.
    >> Share

  554. DENG R, Wang Z, Liu Y, Sun J, et al
    Letter to the Editor: Cautious interpretation of the association between finite treatment and better prognosis in initially HBeAg-negative hepatitis B patients with cirrhosis.
    Hepatology. 2023 Oct 31. doi: 10.1097/HEP.0000000000000654.
    >> Share

  555. GRATACOS-GINES J, Lopez-Pelayo H, Pose E
    Reply: Medications promoting abstinence in alcohol-associated cirrhosis.
    Hepatology. 2023 Oct 31. doi: 10.1097/HEP.0000000000000660.
    >> Share

  556. SELLERS ZM, Assis DN, Paranjape SM, Sathe M, et al
    Cystic fibrosis screening, evaluation and management of hepatobiliary disease consensus recommendations.
    Hepatology. 2023 Oct 26. doi: 10.1097/HEP.0000000000000646.
    >> Share

  557. SONG Y, Ye T, Roberts LR, Larson NB, et al
    Randomization in hepatology: A review of principles, opportunities, and challenges.
    Hepatology. 2023 Oct 24. doi: 10.1097/HEP.0000000000000649.
    >> Share

  558. KAPLAN DE, Bosch J, Ripoll C, Thiele M, et al
    AASLD practice guidance on risk stratification and management of portal hypertension and varices in cirrhosis.
    Hepatology. 2023 Oct 23. doi: 10.1097/HEP.0000000000000647.
    >> Share

  559. YANG T, Qu X, Wang X, Xu D, et al
    Macrophage STING-YAP axis controls hepatic steatosis by promoting autophagic degradation of lipid droplets.
    Hepatology. 2023 Oct 23. doi: 10.1097/HEP.0000000000000638.
    >> Share

  560. CHANG CW, Chen YS, Huang CH, Lin CH, et al
    A genetic basis of mitochondrial DNAJA3 in nonalcoholic steatohepatitis-related hepatocellular carcinoma.
    Hepatology. 2023 Oct 23. doi: 10.1097/HEP.0000000000000637.
    >> Share

  561. OLIVA-VILARNAU N, Beusch CM, Sabatier P, Sakaraki E, et al
    Wnt/beta-catenin and NFkappaB signaling synergize to trigger growth-factor-free regeneration of adult primary human hepatocytes.
    Hepatology. 2023 Oct 23. doi: 10.1097/HEP.0000000000000648.
    >> Share

  562. CAMPANI C, Vallot A, Ghannouchi H, Allaire M, et al
    Impact of radiological response and pattern of progression in patients with hepatocellular carcinoma treated by atezolizumab- bevacizumab.
    Hepatology. 2023 Oct 23. doi: 10.1097/HEP.0000000000000636.
    >> Share

  563. GISH RG, Wong RJ, Di Tanna GL, Kaushik A, et al
    Association between hepatitis delta virus with liver morbidity and mortality: A systematic literature review and meta-analysis.
    Hepatology. 2023 Oct 23. doi: 10.1097/HEP.0000000000000642.
    >> Share

  564. DONGELMANS EJ, Sonneveld MJ, Janssen HLA
    Letter to the Editor: Benefits of stopping therapy in cirrhotic hepatitis B patients, true effect or residual confounding?
    Hepatology. 2023 Oct 20. doi: 10.1097/HEP.0000000000000639.
    >> Share

  565. LIAW YF, Jeng WJ, Chien RN
    Reply: Benefits of stopping therapy in cirrhotic hepatitis B patients, true effect or residual confounding?
    Hepatology. 2023 Oct 20. doi: 10.1097/HEP.0000000000000641.
    >> Share


  566. Erratum: AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma.
    Hepatology. 2023 Oct 16. doi: 10.1097/HEP.0000000000000621.
    >> Share

  567. VONADA A, Wakefield L, Martinez M, Harding CO, et al
    Complete correction of murine phenylketonuria by selection-enhanced hepatocyte transplantation.
    Hepatology. 2023 Oct 12. doi: 10.1097/HEP.0000000000000631.
    >> Share

  568. CHEN P, Dong Z, Zhu W, Chen J, et al
    Noncanonical regulation of HOIL-1 on cancer stemness and sorafenib resistance identifies pixantrone as a novel therapeutic agent for hepatocellular carcinoma.
    Hepatology. 2023 Oct 11. doi: 10.1097/HEP.0000000000000623.
    >> Share

  569. MA S, Chew V
    Unlocking the immune microenvironment of non-alcoholic steatohepatitis-associated hepatocellular carcinoma.
    Hepatology. 2023 Oct 9. doi: 10.1097/HEP.0000000000000626.
    >> Share

  570. THIELE M, Johansen S, Israelsen M, Trebicka J, et al
    Non-invasive assessment of hepatic decompensation.
    Hepatology. 2023 Oct 6. doi: 10.1097/HEP.0000000000000618.
    >> Share

  571. PENNISI G, Enea M, Romero-Gomez M, Bugianesi E, et al
    Risk of liver-related events in metabolic dysfunction-associated steatohepatitis (MASH) patients with fibrosis: A comparative analysis of various risk stratification criteria.
    Hepatology. 2023 Oct 2. doi: 10.1097/HEP.0000000000000616.
    >> Share

  572. XANTHAKOS S
    Rising tide of NAFLD in youth: A warning bell and call to action.
    Hepatology. 2023;78:1017-1019.
    >> Share

  573. ANTON A, Shalaby S, Hernandez-Gea V
    Coagulation meets senescence in NASH!
    Hepatology. 2023;78:1023-1025.
    >> Share

  574. YONEDA M, Nakajima A
    The role of MRI technology in liver evaluation for NAFLD patients: Advancements and opportunities.
    Hepatology. 2023;78:1020-1022.
    >> Share

  575. CHEN W, Sun Y, Chen S, Ge X, et al
    Matrisome gene-based subclassification of patients with liver fibrosis identifies clinical and molecular heterogeneities.
    Hepatology. 2023;78:1118-1132.
    >> Share

  576. LI J, Lu X, Zhu Z, Kalutkiewicz KJ, et al
    Head-to-head comparison of magnetic resonance elastography-based liver stiffness, fat fraction, and T1 relaxation time in identifying at-risk NASH.
    Hepatology. 2023;78:1200-1208.
    >> Share

  577. KIM ??? WR, Iwakiri ???? Y, Lok ??? ASF
    What is in a name? Toward culturally sensitive nomenclature for liver disease in the east and west.
    Hepatology. 2023;78:1032-1034.
    >> Share

  578. MINCIUNA I, Gallage S, Heikenwalder M, Zelber-Sagi S, et al
    Intermittent fasting-the future treatment in NASH patients?
    Hepatology. 2023;78:1290-1305.
    >> Share

  579. CALZADILLA-BERTOT L, Jeffrey GP, Wang Z, Huang Y, et al
    Predicting liver-related events in NAFLD: A predictive model.
    Hepatology. 2023;78:1240-1251.
    >> Share

  580. SEIMIYA T, Otsuka M, Fujishiro M
    Overcoming T-cell exhaustion: New therapeutic targets in HCC immunotherapy.
    Hepatology. 2023;78:1009-1011.
    >> Share


  581. Erratum: Down-Regulation of the Cyclin-Dependent kinase inhibitor p57 is mediated by Jab1/Csn5 in hepatocarcinogenesis.
    Hepatology. 2023;78:E85.
    >> Share

  582. STRAVITZ RT, Fontana RJ, Karvellas C, Durkalski V, et al
    Future directions in acute liver failure.
    Hepatology. 2023;78:1266-1289.
    >> Share

  583. HARTMANN P, Zhang X, Loomba R, Schnabl B, et al
    Global and national prevalence of nonalcoholic fatty liver disease in adolescents: An analysis of the global burden of disease study 2019.
    Hepatology. 2023;78:1168-1181.
    >> Share

  584. KOTULKAR M, Paine-Cabrera D, Abernathy S, Robarts DR, et al
    Role of HNF4alpha-cMyc interaction in liver regeneration and recovery after acetaminophen-induced acute liver injury.
    Hepatology. 2023;78:1106-1117.
    >> Share

  585. DE ANGELIS RIGOTTI F, Wiedmann L, Hubert MO, Vacca M, et al
    Semaphorin 3C exacerbates liver fibrosis.
    Hepatology. 2023;78:1092-1105.
    >> Share

    September 2023
  586. NAHON P, Layese R, Ganne-Carrie N, Moins C, et al
    The clinical and financial burden of nonhepatocellular carcinoma focal lesions detected during surveillance of patients with cirrhosis.
    Hepatology. 2023 Sep 29. doi: 10.1097/HEP.0000000000000615.
    >> Share

  587. LI M, Wang L, Cong L, Wong CC, et al
    Spatial proteomics of immune microenvironment in nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
    Hepatology. 2023 Sep 21. doi: 10.1097/HEP.0000000000000591.
    >> Share

  588. RINELLA ME, Lieu HD, Kowdley KV, Goodman ZD, et al
    A randomized, double-blind, placebo-controlled trial of Aldafermin in patients with nonalcoholic steatohepatitis and compensated cirrhosis.
    Hepatology. 2023 Sep 21. doi: 10.1097/HEP.0000000000000607.
    >> Share

  589. ZHAO X, Kotha S, Nayyar D, Ma X, et al
    Physiologic changes in the hepatopulmonary syndrome before and after liver transplant: A longitudinal and predictor analysis.
    Hepatology. 2023 Sep 21. doi: 10.1097/HEP.0000000000000605.
    >> Share

  590. FAILLI M, Demir S, Del Rio-Alvarez A, Carrillo-Reixach J, et al
    Computational drug prediction in hepatoblastoma by integrating pan-cancer transcriptomics with pharmacological response.
    Hepatology. 2023 Sep 20. doi: 10.1097/HEP.0000000000000601.
    >> Share

  591. GELLERT-KRISTENSEN H, Bojesen SE, Tybjaerg-Hansen A, Stender S, et al
    Telomere length and risk of cirrhosis, hepatocellular carcinoma, and cholangiocarcinoma in 63,272 individuals from the general population.
    Hepatology. 2023 Sep 19. doi: 10.1097/HEP.0000000000000608.
    >> Share

  592. WATT KD, Paul S, Khan MQ, Siddiqui M, et al
    Obesity management for the hepatologist - what to do, how to do it and why.
    Hepatology. 2023 Sep 19. doi: 10.1097/HEP.0000000000000598.
    >> Share

  593. CHEN S, Liao C, Hu H, Liao J, et al
    Hypoxia-driven tumor stromal remodeling and immunosuppressive microenvironment in scirrhous hepatocellular carcinoma.
    Hepatology. 2023 Sep 19. doi: 10.1097/HEP.0000000000000599.
    >> Share

  594. MAESTRI E, Kedei N, Khatib S, Forgues M, et al
    Spatial proximity of Tumor-Immune interactions predicts patient outcome in hepatocellular carcinoma.
    Hepatology. 2023 Sep 19. doi: 10.1097/HEP.0000000000000600.
    >> Share

  595. ZHUANG Y, Ortega-Ribera M, Thevkar Nagesh P, Joshi R, et al
    Bile acid-induced IRF3 phosphorylation mediates cell death, inflammatory responses and fibrosis in cholestasis-induced liver and kidney injury via regulation of ZBP1.
    Hepatology. 2023 Sep 19. doi: 10.1097/HEP.0000000000000611.
    >> Share


  596. December 2023 Hepatology Highlights.
    Hepatology. 2023 Sep 14. doi: 10.1097/HEP.0000000000000594.
    >> Share

  597. WU T, Chen X, Xu K, Dai C, et al
    LIM domain only 7 negatively controls non-alcoholic steatohepatitis in the setting of hyperlipidaemia.
    Hepatology. 2023 Sep 1. doi: 10.1097/HEP.0000000000000585.
    >> Share

    August 2023
  598. GE J, Fontil V, Ackerman S, Pletcher MJ, et al
    Clinical decision support and electronic interventions to improve care quality in chronic liver diseases and cirrhosis.
    Hepatology. 2023 Aug 23. doi: 10.1097/HEP.0000000000000583.
    >> Share

  599. PEISELER M, Tacke F
    Bile duct-associated macrophages enter the spotlight in inflammatory cholestatic liver disease.
    Hepatology. 2023 Aug 22. doi: 10.1097/HEP.0000000000000576.
    >> Share

  600. BOWLUS CL, Levy C
    Optimizing treatment of primary biliary cholangitis: Is good, good enough?
    Hepatology. 2023 Aug 2. doi: 10.1097/HEP.0000000000000556.
    >> Share

  601. DE MUYNCK K, Heyerick L, De Ponti FF, Vanderborght B, et al
    Osteopontin characterizes bile duct associated macrophages and correlates with liver fibrosis severity in primary sclerosing cholangitis.
    Hepatology. 2023 Aug 2. doi: 10.1097/HEP.0000000000000557.
    >> Share


  602. August Hepatology Highlights.
    Hepatology. 2023;78:369-370.
    >> Share

    July 2023

  603. July 2023 Hepatology Highlights.
    Hepatology. 2023;78:1-2.
    >> Share

    June 2023
  604. SOKOL RJ, Gonzales EM, Kamath BM, Baker A, et al
    Predictors of 6-year event-free survival in alagille syndrome patients treated with maralixibat, an ileal bile acid transporter inhibitor.
    Hepatology. 2023 Jun 7. doi: 10.1097/HEP.0000000000000502.
    >> Share

    May 2023

  605. May 2023 Hepatology Highlights.
    Hepatology. 2023;77:1461-1462.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016